protocolSection
dict | hasResults
bool 2
classes | documentSection
dict |
|---|---|---|
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Exmainations including clinical measurement, kinetic and kinematic measurmetns. Behavioral assessments"
}
]
},
"conditionsModule": {
"conditions": [
"ASD"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Seongnam-si",
"contacts": [
{
"email": "[email protected]",
"name": "Minyoung Kim, M.D., Ph.D.",
"phone": "82-31-780-1872",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Korea, Republic of",
"facility": "CHA Bundang Medical Center, CHA University",
"geoPoint": {
"lat": 37.43861,
"lon": 127.13778
},
"state": "Gyeonggi-do",
"status": "RECRUITING",
"zip": "463-712"
}
]
},
"descriptionModule": {
"briefSummary": "This study aims to collect basic data to develop a tool for early screening of autism spectrum disorder (ASD) in children and adolescents through eye tracking and motion analysis."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "19 Years",
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Pilot Study to Develop a Behavior-based Screening Protocol for Early Diagnosis of Autism Spectrum Disorders",
"nctId": "NCT06339359",
"orgStudyIdInfo": {
"id": "2024-02-014",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "K-BSID-Ⅲ"
},
{
"measure": "ADI-R"
},
{
"measure": "M-CHAT"
},
{
"measure": "ADOS-2"
},
{
"measure": "K-WPPSI-Ⅳ"
},
{
"measure": "K-CARS-2"
},
{
"measure": "CBCL"
},
{
"measure": "SCQ"
},
{
"measure": "GMFM"
},
{
"measure": "HFT"
},
{
"measure": "BOT-2"
},
{
"measure": "VMI-6"
},
{
"measure": "SP"
},
{
"measure": "Eye Tracking"
},
{
"measure": "Motion Analysis"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Bundang CHA Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-03-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Colorectal Cancer",
"Colorectal Adenocarcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Brest",
"contacts": null,
"country": "France",
"facility": "Chu Brest",
"geoPoint": {
"lat": 48.3903,
"lon": -4.48628
},
"state": null,
"status": null,
"zip": "29609"
}
]
},
"descriptionModule": {
"briefSummary": "Colorectal cancers (CRC) extending beyond the muscularis mucosae and invading the submucosa without extending beyond it are classified as pT1.Among these, a number of lesions presenting pejorative criteria, notably histopathological, have a significant risk of lymph node invasion, and are therefore candidates for partial colectomy with lymph node dissection. Tumors deemed to be at low risk of lymph node involvement can be treated by endoscopy alone.It should be noted that further surgical intervention is not without comorbid consequences, and that a significant proportion of post-surgical surgical specimens are free of cancerous lesions.The aim of this study is therefore to analyze the current histopathological criteria predictive of lymph node invasion, in order to more accurately select candidates for surgical management."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 400,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PROMOT1",
"briefTitle": "Analysis of Histopathological Factors Predictive of Lymph Node Involvement and Management Practices in pT1 Colorectal Cancers Treated by Primary Endoscopic Resection: a Retrospective Population-based Study (PROMOT1)",
"nctId": "NCT06339346",
"orgStudyIdInfo": {
"id": "29BRC24.0028 - PROMOT1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Analysis of lymph node invasion rates as a function of tumor characteristics"
}
],
"secondaryOutcomes": [
{
"measure": "Population demographics"
},
{
"measure": "lesion characteristics"
},
{
"measure": "management"
},
{
"measure": "recurrence"
},
{
"measure": "survival"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Brest"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-12-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "ACT Now GAIN Later"
},
{
"name": "Control Group"
}
]
},
"conditionsModule": {
"conditions": [
"Psychological Flexibility",
"Child Behavior",
"Relationship, Parent Child",
"Well-Being, Psychological",
"Self-efficacy"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this Randomised Control Trial is to evaluate a Psychologist Guided Self Help Video Parenting Programme based on principles of Acceptance and Commitment Therapy (ACT)The main questions it aims to answer are:Primary Objectives1. Is ACT Now GAIN Later: a Psychologist Guided Self Help Video Parenting Programme based on principles of ACT effective in increasing parental psychological flexibility (measured by Psy-Flex, tool which measures psychological flexibility)? Please find attached.2. Is ACT Now GAIN Later: a Psychologist Guided Self Help Video Parenting Programme based on principles of ACT effective in decreasing child challenging behaviour (measured by the Eyberg Child Behavior Inventory)? Please find attached.Secondary Objectives1. Is ACT Now GAIN Later: an ACT based Parenting Programme, effective in improving parent-child relationships (measured by the Child-Parent Relationship Scale)? Please find attached.2. Does ACT Now GAIN Later increase parental well-being as measured by (Depression Anxiety Stress Scale, Parenting Stress Index and Goal Based Outcome Tool)? Please find attached.3. Does ACT Now GAIN Later increase parental self-efficacy (TOPSE and Parental Sense of Competence scale)? Please find attached.Participants will complete a 7 week psychologist guided parenting intervention. Researchers will compare waitlist groups to see if there are differences in psychological flexibility, child behaviour, parent-child relationships, parental well-being or parental self-efficacy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "This quantitative study will be a two arm randomised control trial with an intervention group and waitlist group.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 150,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "12 Years",
"minimumAge": "3 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Evaluation of ACT Now GAIN Later",
"nctId": "NCT06339333",
"orgStudyIdInfo": {
"id": "RRECB0523EC",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Parental Psychological Flexibility"
},
{
"measure": "Child Behaviour"
}
],
"secondaryOutcomes": [
{
"measure": "Parent-Child Relationships"
},
{
"measure": "Parental Well-Being"
},
{
"measure": "Parental Self-Efficacy"
},
{
"measure": "Parental Self-Efficacy"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University College Dublin"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Endoscopic Sleeve Gastroplasty (ESG)"
},
{
"name": "Apollo OverStitch endoscopic suturing device"
}
]
},
"conditionsModule": {
"conditions": [
"Endoscopic Sleeve Gastroplasty",
"Obesity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Houston",
"contacts": [
{
"email": "[email protected]",
"name": "Thomas R McCarty, MD, MPH",
"phone": "713-363-7436",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Houston Methodist Hospital",
"geoPoint": {
"lat": 29.76328,
"lon": -95.36327
},
"state": "Texas",
"status": "RECRUITING",
"zip": "77030"
},
{
"city": "Sugar Land",
"contacts": [
{
"email": "[email protected]",
"name": "Thomas R McCarty, MD, MPH",
"phone": "713-363-7436",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Houston Methodist Hospital - Sugarland",
"geoPoint": {
"lat": 29.61968,
"lon": -95.63495
},
"state": "Texas",
"status": "RECRUITING",
"zip": "77479"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to evaluate endoscopic sleeve gastroplasty (ESG) for the treatment of obesity. The ESG procedure is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of obesity - patients with a body mass index (BMI) 30-50 kg/m2. This procedure is FDA approved; however, Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-Accredited centers (such as Houston Methodist Hospital) must receive approval from an Institutional Review Board (IRB) in order to perform primary procedures, such as ESG, that are not endorsed by the American Society for Metabolic and Bariatric Surgery (ASMBS)."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Retrospective Registry Study",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 150,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity",
"nctId": "NCT06339320",
"orgStudyIdInfo": {
"id": "PRO00037835",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of participants with technically successful completion of the ESG procedure"
},
{
"measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"
}
],
"secondaryOutcomes": [
{
"measure": "Change in body mass index (BMI) measured by kg/m2"
},
{
"measure": "Change in hemoglobin A1C (%)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "The Methodist Hospital Research Institute"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2033-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2033-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-02-28"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Predictive Cancer Model",
"Gastric Cancer",
"Lymph Node Metastasis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Tianjin",
"contacts": [
{
"email": "[email protected]",
"name": "Jingyu Deng, M.D.",
"phone": "+86-22-23340123",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Cancer Hospital of Tianjin Medical University",
"geoPoint": {
"lat": 39.14222,
"lon": 117.17667
},
"state": "Tianjin",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients",
"nctId": "NCT06339307",
"orgStudyIdInfo": {
"id": "DJY004",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "lymph node metastasis"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Tianjin Medical University Cancer Institute and Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-02-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2023-07-01",
"filename": "Prot_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": false,
"label": "Study Protocol",
"size": 131262,
"typeAbbrev": "Prot",
"uploadDate": "2024-03-17T10:10"
},
{
"date": "2023-07-01",
"filename": "SAP_001.pdf",
"hasIcf": false,
"hasProtocol": false,
"hasSap": true,
"label": "Statistical Analysis Plan",
"size": 158196,
"typeAbbrev": "SAP",
"uploadDate": "2024-03-17T10:11"
},
{
"date": "2023-07-01",
"filename": "ICF_002.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 151390,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-17T10:11"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Clotrimazole Cream"
},
{
"name": "Povidone-Iodine"
}
]
},
"conditionsModule": {
"conditions": [
"Otomycosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Rawalpindi",
"contacts": null,
"country": "Pakistan",
"facility": "Benazir Bhutto Hospital",
"geoPoint": {
"lat": 33.6007,
"lon": 73.0679
},
"state": "Punjab/46000",
"status": null,
"zip": "46000"
}
]
},
"descriptionModule": {
"briefSummary": "Background and Objectives To compare the efficacy of gel foam-soaked pyodine with a single topical application of clotrimazole ointment.Subjects and Methods This randomized controlled trial will include 90 patients presenting to ENT OPD with complaints of earache, watery ear discharge, pruritis, and ear blockage and will be clinically diagnosed as a case of otomycosis on otoscopy. The external auditory canal of the patient will be cleared of fungal debris via suction before treatment In Group A ear canal will be filled with 1% clotrimazole ointment by using an IV catheter and syringe and in Group B pyodine-soaked gel foam will be placed in the external auditory canal. The patients will be followed up on post-treatment days 7 and 14."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 90,
"type": "ACTUAL"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment",
"nctId": "NCT06339294",
"orgStudyIdInfo": {
"id": "ZShabbir",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Treatment Response Based on Otoscopy"
}
],
"secondaryOutcomes": [
{
"measure": "Condition of External Auditory Canal"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Rawalpindi Medical College"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-12-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-06-16"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2023-05-16",
"filename": "Prot_SAP_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": true,
"label": "Study Protocol and Statistical Analysis Plan",
"size": 557916,
"typeAbbrev": "Prot_SAP",
"uploadDate": "2024-03-24T05:10"
},
{
"date": "2023-06-16",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 1206939,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-24T05:13"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "apatinib mesylate+Capecitabine Tablets"
},
{
"name": "apatinib mesylate+Fulvestrant injection"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Breast Cancer"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Previous studies have found good efficacy of (investigator's choice of chemotherapy, or endocrine drug) in combination with apatinib mesylate in the treatment of her-2 negative, chest wall metastatic advanced breast cancer, and the present study proposes to further explore the efficacy of apatinib mesylate in her-2 negative, HR-positive advanced breast cancer."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 68,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer",
"nctId": "NCT06339281",
"orgStudyIdInfo": {
"id": "2023YJZ87",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Progression-free survival"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Li Huiping"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Cognitive training, CogniFit App"
}
]
},
"conditionsModule": {
"conditions": [
"Prehabilitation"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Belgrade",
"contacts": [
{
"email": "[email protected]",
"name": "Vojislava Neskovic, PhD",
"phone": "+381 64 1775 320",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Marija Markovic, MD",
"phone": "+381 62 666653",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Serbia",
"facility": "Military Medical Academy",
"geoPoint": {
"lat": 44.80401,
"lon": 20.46513
},
"state": null,
"status": "RECRUITING",
"zip": "11000"
}
]
},
"descriptionModule": {
"briefSummary": "Postoperative cognitive deficit and its connection with surgery and general anesthesia were first mentioned in the literature in 1955 by Bradford. Cognitive disorders in the postoperative period are postoperative delirium (POD) and postoperative cognitive dysfunction (POCD). POD is an acute dysfunction in cognition, which did not exist preoperatively. Attention deficit disorder is the main symptom of POD and refers to the inability to direct, focus, maintain, or shift attention. Memory impairment, disorientation, or perceptual disturbances may also be present. Cognitive capacity changes in POD patients develop and fluctuate in the first few days after surgery. Unlike POD, there is no formal definition for POCD. Based on data from the existing literature, it is defined as newly diagnosed cognitive deterioration that occurs after surgery. The diagnosis of POCD should be based on pre- and postoperative screening with appropriate psychometric tests. Risk factors for the development of POCD include those related to the surgical procedure, anesthesia, or the patient himself. Compared to less invasive and shorter operations, there is a higher risk of developing POCD after major, invasive, and long-term operations. Additional risk factors are intraoperative (intraoperative bleeding, perioperative transfusion treatment, hypotension) and postoperative complications (respiratory insufficiency, pneumonia, atelectasis, bronchospasm, bronchopleural fistula, and pulmonary edema). Presurgical optimization (Prehabilitation) is a widespread concept that aims to improve the general condition of the patient or optimize comorbidities before major surgery. Prehabilitation is primarily focused on improving physical ability and nutritional status, but it is developing in the direction of a multimodal approach that includes measures to reduce stress and anxiety. Psychological factors are increasingly recognized as an essential element of prehabilitation and are often added to prehabilitation programs.Older patients, who meet the diagnostic criteria for frailty and are at risk of developing postoperative complications such as cognitive function disorders are increasinglyundergoing lung resection. These complications can affect the outcome and speed of postoperative recovery."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "After setting the indication for operative treatment, patients who meet the criteria for inclusion in the study, after signing the informed consent, will be randomized into two groups:1. The first group (intervention) where the patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.2. The second group (control) where patients receive standard treatment.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "60 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "COGNITION",
"briefTitle": "Cognitive and Physical Optimization in Prevention of Postoperative Cognitive Deficit in Elderly With Lung Resection",
"nctId": "NCT06339268",
"orgStudyIdInfo": {
"id": "MMABelgrade",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Postoperative cognitive dysfunction"
},
{
"measure": "Perioperative depression and anxiety"
},
{
"measure": "Postoperative delirium"
},
{
"measure": "Functional status and postoperative recovery"
},
{
"measure": "Functional status and postoperative recovery"
},
{
"measure": "Postoperative recovery"
},
{
"measure": "Functional status and postoperative recovery"
}
],
"secondaryOutcomes": [
{
"measure": "Overall outcome: Complication rate"
},
{
"measure": "Overall outcome: Morbidity"
},
{
"measure": "Overall outcome: Mortality"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Military Medical Academy, Belgrade, Serbia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-11-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Diffuse Low Grade B-Cell Lymphoma",
"Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
"Mantle Cell Lymphoma",
"Follicular Lymphoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milan",
"contacts": [
{
"email": "[email protected]",
"name": "Paolo Corradini, Professor",
"phone": "+39 02 2390 2950",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Anisa Bermema, PhD",
"phone": "+39 02 2390 3145",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Annalisa Chiappella, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Anna Dodero, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Fondazione IRCCS Istituto Nazionale Tumori",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "RECRUITING",
"zip": "20133"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 5300,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "CART-SIE",
"briefTitle": "Italian Observational Study on CAR-T Therapy for Lymphoma",
"nctId": "NCT06339255",
"orgStudyIdInfo": {
"id": "INT 180/19",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Characterization of biomarkers of early response (circulating tumor cell free DNA versus PET and CT scans)"
},
{
"measure": "Characterization of toxicity biomarkers"
},
{
"measure": "Analysis of the immune reconstitution"
},
{
"measure": "Analysis of the CAR-T expression"
},
{
"measure": "Influence of PET quantitative parameters: tMTV changes between baseline and +30 and +90 after CAR T-cell infusion (ΔSUV max) related to outcome"
},
{
"measure": "Influence of PET quantitative parameters: Distance max"
},
{
"measure": "Influence of PET quantitative parameters: Distance max bulky"
}
],
"primaryOutcomes": [
{
"measure": "Feasibility of the CAR-T cells treatment in lymphomas in the italian real life practice"
},
{
"measure": "Efficacy of the CAR-T cells treatment in lymphomas in the italian real life practice"
}
],
"secondaryOutcomes": [
{
"measure": "Evaluation of Outcome: Overall Response rate (ORR), according to Lugano criteria."
},
{
"measure": "Evaluation of Outcome: Overall survival (OS), according to Lugano criteria."
},
{
"measure": "Evaluation of Outcome: Progression free survival (PFS)"
},
{
"measure": "Evaluation of Outcome: duration of response (DoR)"
},
{
"measure": "Evaluation of Outcome: Overall Response rate (ORR)"
},
{
"measure": "Evaluation of Outcome: Overall survival (OS)"
},
{
"measure": "Evaluation of Outcome: non-relapse mortality (NRM)"
},
{
"measure": "Evaluation of safety (CRS, neurotoxicity, infections, cytopenias, B cell aplasia, second malignancies) with particular attention to the safety in the new indications"
},
{
"measure": "Evaluation of bridging therapy: safety"
},
{
"measure": "Evaluation of bridging therapy: efficay"
},
{
"measure": "Evaluation of salvage therapy after CAR-T failure"
},
{
"measure": "Evaluation of salvage therapy after CAR-T failure"
},
{
"measure": "Comparison of the different CAR T-cell products (time from patient screening to infusion, disease response and safety)"
},
{
"measure": "Comparison of the different histotypes (PMBCL, DLBCL, MCL FL) according to CAR-T cell products"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Annalisa Chiappella"
},
{
"name": "Cristiana Carniti"
},
{
"name": "Anna Dodero"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Paolo Corradini"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2019-10-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Furmonertinib"
}
]
},
"conditionsModule": {
"conditions": [
"NSCLC"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nanjing",
"contacts": [
{
"email": "[email protected]",
"name": "fang S Cun",
"phone": "83728558",
"phoneExt": "025",
"role": "CONTACT"
}
],
"country": "China",
"facility": "Nanjing Brain Hospital",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": "Jiangsu",
"status": "RECRUITING",
"zip": "210029"
}
]
},
"descriptionModule": {
"briefSummary": "Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis",
"nctId": "NCT06339242",
"orgStudyIdInfo": {
"id": "2024-01-NSCLC",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "LM-PFS（progression-free survival）"
},
{
"measure": "LM-ORR（Objective response rate）"
}
],
"secondaryOutcomes": [
{
"measure": "LM-OS"
},
{
"measure": "Incidence of Treatment-Emergent Adverse Events"
},
{
"measure": "PFS"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Jiangsu Province Nanjing Brain Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "proteinuria"
}
]
},
"conditionsModule": {
"conditions": [
"Surgery",
"Proteinuria",
"Mortality"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "We aimed to assess the association between postoperative new-onset proteinuria, all-cause mortality, and decline in kidney function in Chinese people who underwent surgery. The exposure variable was the dipstick proteinuria values from the initial postoperative urinalysis within 30 days after surgery, categorized as negative, trace, 1+, and ≥2+. The primary outcome was 30-day mortality. The secondary outcomes included 1-year mortality and composite kidney outcome assessed using the postoperative estimated glomerular filtration rate."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 2983899,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "16 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Postoperative New-onset Proteinuria and Adverse Outcomes.",
"nctId": "NCT06339229",
"orgStudyIdInfo": {
"id": "FSYYY-2024-12",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "mortality"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Yaozhong Kong"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-11-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2000-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)"
}
]
},
"conditionsModule": {
"conditions": [
"Gastric Cancer"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer Previously Treated with Immunotherapy"
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.",
"nctId": "NCT06339216",
"orgStudyIdInfo": {
"id": "OBU-BJ-GC-II-011",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "ORR"
}
],
"secondaryOutcomes": [
{
"measure": "PFS"
},
{
"measure": "DCR"
},
{
"measure": "OS"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Chinese PLA General Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Irrisept"
},
{
"name": "Normal Saline"
}
]
},
"conditionsModule": {
"conditions": [
"Cesarean Section Complications",
"Cesarean Section; Infection"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Loma Linda",
"contacts": [
{
"email": "[email protected]",
"name": "Nikia Gray Hutto, AS",
"phone": "909-558-4000",
"phoneExt": "44428",
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Loma Linda University",
"geoPoint": {
"lat": 34.04835,
"lon": -117.26115
},
"state": "California",
"status": null,
"zip": "92354"
}
]
},
"descriptionModule": {
"briefSummary": "This investigator-initiated, open-label, randomized controlled trial will explore the effects of two treatment arms, comparing standard treatment with normal saline against Irrisept, a jet lavage solution containing a low concentration of Chlorhexidine Gluconate (CHG) at 0.05% in 99.95% sterile water for irrigation. The study aims to evaluate the impact on postoperative wound healing in patients who have undergone cesarean delivery."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 400,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Intraoperative Wound Irrigation in Cesarean Section",
"nctId": "NCT06339203",
"orgStudyIdInfo": {
"id": "5240002",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Composite wound evaluation after caesarean delivery"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Irrimax Corporation"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Loma Linda University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Venepuncture"
}
]
},
"conditionsModule": {
"conditions": [
"Neurodegenerative Diseases",
"Dementia"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Box Hill",
"contacts": [
{
"email": "[email protected]",
"name": "Svetlana Ivanic",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Australia",
"facility": "Box Hill Hospital",
"geoPoint": {
"lat": -37.81887,
"lon": 145.12545
},
"state": "Victoria",
"status": "RECRUITING",
"zip": "3128"
},
{
"city": "Wantirna",
"contacts": [
{
"email": null,
"name": "Sarah Shue",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Australia",
"facility": "Wantirna Health",
"geoPoint": {
"lat": -37.85,
"lon": 145.21667
},
"state": "Victoria",
"status": "RECRUITING",
"zip": "3152"
}
]
},
"descriptionModule": {
"briefSummary": "This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "NAVAIDD",
"briefTitle": "Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis",
"nctId": "NCT06339190",
"orgStudyIdInfo": {
"id": "E21-006-72840",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Modified Rankin Scale"
},
{
"measure": "Montreal Cognitive Assessment score"
},
{
"measure": "Hospital Anxiety and Depression Scale score"
},
{
"measure": "Clinical Global Impression score"
},
{
"measure": "WHO Disability Assessment 12-item telephone interview score"
},
{
"measure": "WHO Disability Assessment 36-item self report score"
},
{
"measure": "DNA sample for testing known pathogenic dementia mutations"
}
],
"primaryOutcomes": [
{
"measure": "Nfl correlation with neurodegeneration"
}
],
"secondaryOutcomes": [
{
"measure": "Change in speech processing"
},
{
"measure": "Change in language processing"
},
{
"measure": "Change in Direct Magnitude Estimation"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Eastern Health"
},
{
"name": "University of Melbourne"
},
{
"name": "Wake Forest University"
},
{
"name": "Deakin University"
},
{
"name": "The Florey Institute of Neuroscience and Mental Health"
},
{
"name": "Invitae Corporation"
},
{
"name": "Redenlab"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Monash University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-08-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Lymphohistiocytosis, Hemophagocytic",
"Secondary Hemophagocytic Lymphohistiocytosis",
"Macrophage Activation Syndrome",
"Hyperinflammatory Syndromes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bethesda",
"contacts": [
{
"email": "[email protected]",
"name": "NIH Clinical Center Office of Patient Recruitment (OPR)",
"phone": "800-411-1222",
"phoneExt": "TTY dial 711",
"role": "CONTACT"
}
],
"country": "United States",
"facility": "National Institutes of Health Clinical Center",
"geoPoint": {
"lat": 38.98067,
"lon": -77.10026
},
"state": "Maryland",
"status": "RECRUITING",
"zip": "20892"
}
]
},
"descriptionModule": {
"briefSummary": "Background:Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH.Objective:To learn about sHLH and why some people get it and others do not.Eligibility:Adults aged 18 years and older with sHLH.Design:Participants will be admitted to the study based on a review of their medical records. Those who join will have at least 3 clinical evaluations over 9 to 12 months. These may occur during an inpatient hospitalization if they require medical care or in the outpatient clinic.Participants will also have a physical exam at each visit. Up to half a cup of blood will be drawn at each visit. Participants may also have their blood drawn by their own doctors, who will send the samples to the researchers. Researchers may also contact these participants by telephone or video calls.The blood will be used for clinical tests as well as research. No new treatments will be administered as part of this study; however, standard medications and treatments may be recommended.Participants may opt to continue their visits once a year for 3 more years. Participants may also opt for an extra clinial evaluation 1 week after starting a new treatment...."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 200,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "120 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study",
"nctId": "NCT06339177",
"orgStudyIdInfo": {
"id": "10001899",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "001899-I",
"link": null,
"type": null
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Identify immunologic mechanisms involved in the pathogenesis of sHLH from a variety of predisposing conditions."
}
],
"secondaryOutcomes": [
{
"measure": "Prospectively define acute and longitudinal clinical profiles that predict key clinical outcomes."
},
{
"measure": "Compare clinical and immune profiles between the classically defined HLH subgroups."
},
{
"measure": "Improve the understanding of the pathogenesis of sHLH."
},
{
"measure": "Characterize risk factors to identify populations at risk for developing sHLH."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "NIH",
"name": "National Institute of Allergy and Infectious Diseases (NIAID)"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2031-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2030-10-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "skills and learning quality in breech delivery"
}
]
},
"conditionsModule": {
"conditions": [
"Breech Presentation; Before Labor"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pescara",
"contacts": null,
"country": "Italy",
"facility": "Claudio Celentano",
"geoPoint": {
"lat": 42.4584,
"lon": 14.20283
},
"state": "PE",
"status": null,
"zip": "65100"
}
]
},
"descriptionModule": {
"briefSummary": "Breech delivery is one of the mail topic in emergency obstetrics for Italian Board of Obstetrics and Gynecology. Formal frontal lecture and digital learning represent nowadays the two typical learning methods. A bedside evaluation it's not feasible due to rarity of such emergency, due to the common senior physicians involvement when it occurs, and due to medico-legal risks. Mannequin scenario represents the best way of skill evaluation"
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "38 Years",
"minimumAge": "24 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "Breech",
"briefTitle": "Breech Delivery Skills. Resident Learning Program",
"nctId": "NCT06339164",
"orgStudyIdInfo": {
"id": "ObGynEASC006",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Skills capacities"
},
{
"measure": "Skills capacities"
}
],
"secondaryOutcomes": [
{
"measure": "learning qualities"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "G. d'Annunzio University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Dexamethasone before surgery"
},
{
"name": "Dexamethasone before and 12 hours after surgery"
},
{
"name": "Dexamethasone before and 24 hours after surgery"
}
]
},
"conditionsModule": {
"conditions": [
"Osteo Arthritis Knee",
"Pain, Postoperative"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Khlong Luang",
"contacts": [
{
"email": "[email protected]",
"name": "Yot Tanariyakul, M.D.",
"phone": "6683930257",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Yot Tanariyakul, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Piya Pinsornsak, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Thammasat University Hospital",
"geoPoint": {
"lat": 14.06467,
"lon": 100.64578
},
"state": "Pathum Thani",
"status": "RECRUITING",
"zip": "12120"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to investigate the efficacy of single dose and double dose of dexamethasone after primary total knee replacement.The main question\\[s\\] it aims to answer \\[is/are\\]:Does 24 hours-interval of double dose of dexamethasone have better analgesic effect than single dose and 12 hours interval of double dose of dexamethasone after primary total joint replacement?Researchers will compare double dose of dexamethasone group to see if \\[insert effects\\].Participants will \\[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\\]."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "85 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Comparing Single Dose and Multiple Dose of Dexamethasone Post TKA",
"nctId": "NCT06339151",
"orgStudyIdInfo": {
"id": "TUH multiple dexamethasone TKA",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Pain at rest and motion"
}
],
"secondaryOutcomes": [
{
"measure": "Nausea and vomiting"
},
{
"measure": "Morphine consumption"
},
{
"measure": "Blood sugar level"
},
{
"measure": "CRP level"
},
{
"measure": "Range of motion"
},
{
"measure": "Length of hospital stay"
},
{
"measure": "Complication"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Thammasat University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-10-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-23"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Non-Interventional Study"
}
]
},
"conditionsModule": {
"conditions": [
"Chromophobe Renal Cell Carcinoma",
"Clear Cell Papillary Renal Tumor",
"Clear Cell Renal Cell Carcinoma",
"Kidney Oncocytoma",
"Papillary Renal Cell Carcinoma",
"Urothelial Carcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Rochester",
"contacts": [
{
"email": "[email protected]",
"name": "Clinical Trials Referral Office",
"phone": "855-776-0015",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "John C. Cheville, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "John B. Kisiel, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Mayo Clinic in Rochester",
"geoPoint": {
"lat": 44.02163,
"lon": -92.4699
},
"state": "Minnesota",
"status": "RECRUITING",
"zip": "55905"
}
]
},
"descriptionModule": {
"briefSummary": "This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 874,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study",
"nctId": "NCT06339138",
"orgStudyIdInfo": {
"id": "17-010944",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "CTRP (Clinical Trial Reporting Program)",
"id": "NCI-2024-00971",
"link": null,
"type": "REGISTRY"
},
{
"domain": "Mayo Clinic in Rochester",
"id": "17-010944",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Mayo Clinic"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-01-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-01-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2018-02-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Fall prevention algorithm"
},
{
"name": "Inspiren camera visualization"
}
]
},
"conditionsModule": {
"conditions": [
"Falls and Falls With Injury"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Annually, in the United States there are 700,000 - 1,000,000 inpatient falls reported, and one-third of patients sustain an injury. The average estimated cost per fall is $6,694, resulting in over $1.4 -1.9 billion dollars in losses each year (AHRQ, 2017). This study aims to compare the impact of different fall prevention strategies on the rate of occurrence of falls and falls with injury in an academic medical center on three adult medical units. While maintaining the usual standard of care for fall prevention, each unit will add one of the following: (1) use of a fall risk alert to nurses using an algorithm based on electronic health record data or (2) computerized camera visualization or (3) a combination of both."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "An observational cohort, mixed-methods study design will be conducted to determine the impact and effectiveness of usual care and three different fall prevention strategies that exceed the standard of care on three inpatient units at MGH over one year. Unit 1 will employ streaming analytics and the MGH algorithm only, Unit 2 will employee Inspiren's AUGI computer visualization only and Unit 3 will employ the combined streaming analytic/MGH algorithm and Inspiren's AUGI device. Unit 4, the control unit, will serve as an internal comparison group from the same institution. In addition to the study interventions all four units will continue to maintain usual MGH evidence-based practice, standards of care for fall prevention.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 4500,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls",
"nctId": "NCT06339125",
"orgStudyIdInfo": {
"id": "2023p003637",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Falls"
},
{
"measure": "Falls with injury"
}
],
"secondaryOutcomes": [
{
"measure": "Nurse perceptions"
},
{
"measure": "Nurse perceptions"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Crico"
},
{
"name": "Inspiren Inc"
},
{
"name": "RGI Informatics LLC"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Massachusetts General Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Playing with toy nebulizer"
},
{
"name": "Cartoon"
}
]
},
"conditionsModule": {
"conditions": [
"Fear",
"Anxiety",
"Inhalant Use"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mersin",
"contacts": null,
"country": "Turkey",
"facility": "Tarsus State Hospital",
"geoPoint": {
"lat": 36.79526,
"lon": 34.61792
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This research was planned as a randomized controlled experimental type to determine the effect of playing with a toy nebulizer and watching cartoons on children's fear and physiological parameters in 3-6 year old children who were administered inhaler medication. The population of the study, planned as a randomized controlled experimental study, will consist of 4-6 year old children who apply to Tarsus State Hospital pediatric services and receive inhaler treatment. According to the power analysis performed for the sample size, the power of the sample was calculated with the G\\*Power 3.1 program, in line with the literature (Durak 2019; Özsamuri 2020). While the amount of Type I error was 0.05 and the power of the test was 0.95 (α= 0.05, 1-β= 0.95), the minimal sample size was calculated as 105 children (35 children in each group). Considering the possible losses from the sample for any reason during the study period, it was planned to increase the number of samples by 10% and include 38 children in the study and control groups. Child Information Form, Fear Assessment Scale and Child Anxiety Scale-State Scale will be used to collect data."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A randomized controlled experimental study",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 114,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "6 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Playing With a Toy Nebulizer and Watching Cartoons on the Fear and Anxiety on Children",
"nctId": "NCT06339112",
"orgStudyIdInfo": {
"id": "2024/10",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "fear"
},
{
"measure": "anxiety"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Tarsus University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Conventional physical therapy program"
},
{
"name": "Loaded gait training"
}
]
},
"conditionsModule": {
"conditions": [
"Cerebral Palsy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Giza",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of Physical Therapy, Cairo University",
"geoPoint": {
"lat": 30.00808,
"lon": 31.21093
},
"state": "Cairo",
"status": null,
"zip": "12613"
}
]
},
"descriptionModule": {
"briefSummary": "A randomized controlled trial aimed to evaluate the additional effect loaded gait training to conventional physical therapy program on gross motor function and the knee extensors strength in children with bilateral spastic cerebral palsy. Children were divided randomly into two equal groups. The control group received a conventional physical therapy program, while the intervention group received the same program plus loaded gait training. Gross motor functions and knee extensor strength were measured."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Children were randomly assigned into two equal groups.",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "Double blinding. Parents were also blinded.",
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 52,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "7 Years",
"minimumAge": "5 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Loaded Gait Training on Gross Motor Function in Cerebral Palsy",
"nctId": "NCT06339099",
"orgStudyIdInfo": {
"id": "P.T.REC/012/002489",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Gross motor function"
},
{
"measure": "knee extensor strength"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cairo University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-03-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-10-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-02-26"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Semaglutide Injection"
},
{
"name": "Semaglutide Injection(Ozempic®)"
},
{
"name": "Metformin"
}
]
},
"conditionsModule": {
"conditions": [
"Type 2 Diabetes Mellitus"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous injection) as add-on to metformin for 32 weeks.Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 478,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes",
"nctId": "NCT06339086",
"orgStudyIdInfo": {
"id": "BPR-201-I-III-01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in HbA1c"
}
],
"secondaryOutcomes": [
{
"measure": "Change in HbA1c"
},
{
"measure": "Change in FPG"
},
{
"measure": "Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5%"
},
{
"measure": "Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5% with no hypoglycemic event"
},
{
"measure": "Change in Body Weight"
},
{
"measure": "Proportion of participants with Weight Loss≥5%, ≥10% and ≥15%"
},
{
"measure": "Change in Diastolic and Systolic Blood Pressure"
},
{
"measure": "Changes in Blood Lipids"
},
{
"measure": "Incidence and severity of Adverse Events"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Chengdu Brilliant Pharmaceutical Co., Ltd."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-08-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "mechanical ventilation"
}
]
},
"conditionsModule": {
"conditions": [
"Wounds and Injuries",
"Ventilation Therapy; Complications"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nanjing",
"contacts": null,
"country": "China",
"facility": "the General Surgical Department of Jinling Hospital",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": "Jiangsu",
"status": null,
"zip": "210002"
}
]
},
"descriptionModule": {
"briefSummary": "Critically ill patients often require tracheal intubation for mechanical ventilation, and timely weaning is crucial for airway management and reducing complications. However, there is currently a lack of an effective tool to predict weaning time in critically ill patients. This retrospective study established an effective nomogram model for predicting the time of weaning from mechanical ventilation in abdominal trauma patients by considering multiple perspectives. The model has been validated and demonstrated good performance in terms of discrimination, calibration, and clinical utility. Moreover, the model can effectively predict the prognosis of critically ill patients. The findings of this study have important implications for guiding respiratory management in clinically critically ill patients, particularly trauma patients."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 1023,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "CT-based Model for Predicting Prolonged Weaning in Patients With Abdominal Trauma",
"nctId": "NCT06339073",
"orgStudyIdInfo": {
"id": "2021NZKY-045-01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Prolonged mechanical ventilation"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Jinling Hospital, China"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-02-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-12-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-10-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Experimental: Arm 1 Organ preservation"
},
{
"name": "Active Comparator: Arm 2 Surgery"
}
]
},
"conditionsModule": {
"conditions": [
"Esophageal Cancer"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group).The 3-year overall survival rate is the primary outcome."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "Randomize patients who meet the inclusion criteria Grouping, randomly assigned to the experimental group in a 1:1 ratio (organ preservation strategy after neoadjuvant chemotherapy combined with immunotherapy) And the control group (limited time for esophageal cancer radical surgery after neoadjuvant radiotherapy and chemotherapy)",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 356,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PALACE3",
"briefTitle": "An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).",
"nctId": "NCT06339060",
"orgStudyIdInfo": {
"id": "RTS-022",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "3-year overall survival rate"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ruijin Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-03-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Projector Kaleidoscope"
},
{
"name": "Cartoon"
}
]
},
"conditionsModule": {
"conditions": [
"Anxiety and Fear",
"Pain",
"Surgery"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mersin",
"contacts": null,
"country": "Turkey",
"facility": "Tarsus State Hospital",
"geoPoint": {
"lat": 36.79526,
"lon": 34.61792
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The research will be conducted with children hospitalized in Tarsus State Hospital Children's Clinics and who meet the sampling criteria.The population of the study, which is planned as a randomized controlled experimental study, will consist of children aged 4-10 years old who are admitted to the pediatric surgery service of Tarsus State Hospital and will undergo outpatient surgical intervention.In collecting research data; the Introductory Information Form, Child Anxiety Scale, Child Fear Scale, Wong-Baker Pain Scale and Vital Signs Follow-up Form will be used."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A randomized controlled experimental study",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 90,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "10 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Projector Kaleidoscope and Cartoons on Anxiety, Fear, and Pain in Children",
"nctId": "NCT06339047",
"orgStudyIdInfo": {
"id": "2024/09",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Anxiety"
},
{
"measure": "Fear"
},
{
"measure": "Pain after surgery"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Tarsus University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Lithium"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Parkinson Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Williamsville",
"contacts": [
{
"email": "[email protected]",
"name": "Thomas Guttuso, MD",
"phone": "716-932-6080",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Amelia Cheney",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Thomas Guttuso, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "UBMD Neurology",
"geoPoint": {
"lat": 42.96395,
"lon": -78.73781
},
"state": "New York",
"status": null,
"zip": "14221"
}
]
},
"descriptionModule": {
"briefSummary": "This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Double-blind, placebo-controlled",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": [
"PHASE1",
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Repurposing Lithium for Parkinson's Disease: a RCT",
"nctId": "NCT06339034",
"orgStudyIdInfo": {
"id": "STUDY",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Adverse events"
}
],
"primaryOutcomes": [
{
"measure": "MRI-derived free water (FW) levels."
},
{
"measure": "Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression"
},
{
"measure": "Serum neurofilament light chain (NfL)"
}
],
"secondaryOutcomes": [
{
"measure": "PBMC superoxide dismutase type-1 (SOD-1) mRNA expression"
},
{
"measure": "PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio"
},
{
"measure": "PBMC pThr308 and pS473/total protein kinase B (Akt) ratios"
},
{
"measure": "Serum interleukin-6"
},
{
"measure": "Serum glial fibrillary acidic protein (GFAP)"
},
{
"measure": "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination)"
},
{
"measure": "Montreal Cognitive Assessment (MoCA)"
},
{
"measure": "Parkinson's Anxiety Scale"
},
{
"measure": "Geriatric Depression Scale-15"
},
{
"measure": "Fatigue Severity Scale"
},
{
"measure": "Insomnia Severity Index"
},
{
"measure": "Parkinson's Disease Questionnaire-8"
},
{
"measure": "Levodopa equivalent daily dose (LEDD)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "The Cure Parkinson's Trust"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "State University of New York at Buffalo"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "OCT-guided PCI"
},
{
"name": "Conventional angiography-based PCI"
},
{
"name": "DAPT de-escalation"
},
{
"name": "default DAPT regimen"
}
]
},
"conditionsModule": {
"conditions": [
"Optical Coherence Tomography",
"Dual Antiplatelet Therapy",
"Antiplatelet De-escalation",
"Neointimal Coverage",
"ST Elevation Myocardial Infarction"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shenyang",
"contacts": [
{
"email": "[email protected]",
"name": "Yaling Han, Dr",
"phone": "+86-24-28897313",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Yaling Han, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Yang Li, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Yi Li, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "China",
"facility": "Northern Hospital",
"geoPoint": {
"lat": 41.79222,
"lon": 123.43278
},
"state": "Liaoning",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.Based on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"EARLY_PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "OCT or Angiography Guided De-escalation of DAPT",
"nctId": "NCT06339021",
"orgStudyIdInfo": {
"id": "DAPT-OCT",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Neointimal thickness after DES implantation"
}
],
"secondaryOutcomes": [
{
"measure": "Major adverse cardiovascular and cerebrovascular events (MACCE)"
},
{
"measure": "BARC types 2-5 bleeding"
},
{
"measure": "In-stent thrombosis"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Shenyang Northern Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "LY3650150"
},
{
"name": "Placebo"
},
{
"name": "Standard therapy for INCS"
}
]
},
"conditionsModule": {
"conditions": [
"Perennial Allergic Rhinitis (PAR)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "California City",
"contacts": [
{
"email": null,
"name": null,
"phone": "949-276-4917",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Warner Carr",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Southern California Research",
"geoPoint": {
"lat": 35.1258,
"lon": -117.9859
},
"state": "California",
"status": null,
"zip": "92691"
},
{
"city": "Inglewood",
"contacts": [
{
"email": null,
"name": null,
"phone": "310-878-2636",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Soheil Hekmat",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "310 Clinical Research",
"geoPoint": {
"lat": 33.96168,
"lon": -118.35313
},
"state": "California",
"status": null,
"zip": "90301"
},
{
"city": "San Diego",
"contacts": [
{
"email": null,
"name": null,
"phone": "858-268-2368",
"phoneExt": "143",
"role": "CONTACT"
},
{
"email": null,
"name": "Bob Geng",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Allergy and Asthma",
"geoPoint": {
"lat": 32.71533,
"lon": -117.15726
},
"state": "California",
"status": null,
"zip": "92123"
},
{
"city": "Colorado Springs",
"contacts": [
{
"email": null,
"name": null,
"phone": "719-473-8330 x5",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Luke Webb",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Asthma and Allergy Associates, PC",
"geoPoint": {
"lat": 38.83388,
"lon": -104.82136
},
"state": "Colorado",
"status": null,
"zip": "80907-6231"
},
{
"city": "Aventura",
"contacts": [
{
"email": null,
"name": null,
"phone": "305-931-7583",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jaime Landman",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Florida Center For Allergy & Asthma Care Aventura",
"geoPoint": {
"lat": 25.95648,
"lon": -80.13921
},
"state": "Florida",
"status": null,
"zip": "33180"
},
{
"city": "Lexington",
"contacts": [
{
"email": null,
"name": null,
"phone": "859-303-7191",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "William Greisner",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Bluegrass Allergy Research",
"geoPoint": {
"lat": 37.98869,
"lon": -84.47772
},
"state": "Kentucky",
"status": null,
"zip": "40509"
},
{
"city": "Greenfield",
"contacts": [
{
"email": null,
"name": null,
"phone": "414-529-8519",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Gary Steven",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Allergy, Asthma & Sinus Center",
"geoPoint": {
"lat": 42.58759,
"lon": -72.59953
},
"state": "Massachusetts",
"status": null,
"zip": "53228"
},
{
"city": "Ypsilanti",
"contacts": [
{
"email": null,
"name": null,
"phone": "734-528-0477",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jeffrey Leflein",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Respiratory Medicine Research Institute of Michigan, PLC",
"geoPoint": {
"lat": 42.24115,
"lon": -83.61299
},
"state": "Michigan",
"status": null,
"zip": "48197"
},
{
"city": "Minneapolis",
"contacts": [
{
"email": null,
"name": null,
"phone": "612-333-2200",
"phoneExt": "378",
"role": "CONTACT"
},
{
"email": null,
"name": "Gary Berman",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Clinical Research Institute",
"geoPoint": {
"lat": 44.97997,
"lon": -93.26384
},
"state": "Minnesota",
"status": null,
"zip": "55402"
},
{
"city": "Saint Louis",
"contacts": [
{
"email": null,
"name": null,
"phone": "314-991-5117",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Robert Onder",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Allergy and Asthma Consultants",
"geoPoint": {
"lat": 38.62727,
"lon": -90.19789
},
"state": "Missouri",
"status": null,
"zip": "63141"
},
{
"city": "Teaneck",
"contacts": [
{
"email": null,
"name": "Patrick Perin",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Dr. Patrick Perin",
"geoPoint": {
"lat": 40.8976,
"lon": -74.01597
},
"state": "New Jersey",
"status": null,
"zip": "07666"
},
{
"city": "Cincinnati",
"contacts": [
{
"email": null,
"name": null,
"phone": "314-991-5117",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "David Bernstein",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Bernstein Clinical Research Center, LLC",
"geoPoint": {
"lat": 39.12713,
"lon": -84.51435
},
"state": "Ohio",
"status": null,
"zip": "45236"
},
{
"city": "Portland",
"contacts": [
{
"email": null,
"name": null,
"phone": "503-238-6233",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Anthony Montanaro",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Northwest Research Center",
"geoPoint": {
"lat": 45.52345,
"lon": -122.67621
},
"state": "Oregon",
"status": null,
"zip": "97202"
},
{
"city": "Pittsburgh",
"contacts": [
{
"email": null,
"name": null,
"phone": "412-833-4051",
"phoneExt": "116",
"role": "CONTACT"
},
{
"email": null,
"name": "Michael Palumbo",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Allergy and Clinical Immunology Associates",
"geoPoint": {
"lat": 40.44062,
"lon": -79.99589
},
"state": "Pennsylvania",
"status": null,
"zip": "15241"
},
{
"city": "Kerrville",
"contacts": [
{
"email": null,
"name": null,
"phone": "830-896-1433",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Dale Mohar",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Kerrville Allergy and Asthma Associates",
"geoPoint": {
"lat": 30.04743,
"lon": -99.14032
},
"state": "Texas",
"status": null,
"zip": "78028"
},
{
"city": "Waco",
"contacts": [
{
"email": null,
"name": null,
"phone": "254-741-8151",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Niran Amar",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Allergy Asthma Research Institute",
"geoPoint": {
"lat": 31.54933,
"lon": -97.14667
},
"state": "Texas",
"status": null,
"zip": "76712"
}
]
},
"descriptionModule": {
"briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 450,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)",
"nctId": "NCT06339008",
"orgStudyIdInfo": {
"id": "18789",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Eli Lilly and Company",
"id": "J2T-MC-KGBT",
"link": null,
"type": "OTHER"
},
{
"domain": "EU Clinical Trial Number",
"id": "2023-508817-18-00",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16"
}
],
"secondaryOutcomes": [
{
"measure": "Mean CFBL in Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version [RQLQ(S)] at week 16"
},
{
"measure": "Mean CFBL in RQLQ(S) at week 56"
},
{
"measure": "Mean CFBL in TNSS at Week 4"
},
{
"measure": "Mean CFBL in TNSS at Week 56"
},
{
"measure": "Mean CFBL in Postnasal drip score at Week 16"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Eli Lilly and Company"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-15"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-12"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "LY3650150"
},
{
"name": "Placebo"
},
{
"name": "Standard therapy for INCS"
}
]
},
"conditionsModule": {
"conditions": [
"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mandeville",
"contacts": [
{
"email": null,
"name": "James Connolly",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "South Louisiana Ear, Nose, Throat & Facial Plastic Surgery - PPDS",
"geoPoint": {
"lat": 30.35825,
"lon": -90.06563
},
"state": "Louisiana",
"status": null,
"zip": "70448"
},
{
"city": "McKinney",
"contacts": [
{
"email": null,
"name": "Dale Ehmer, Jr.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Ear Nose and Throat Associates of Texas PA",
"geoPoint": {
"lat": 33.19762,
"lon": -96.61527
},
"state": "Texas",
"status": null,
"zip": "75070-5735"
},
{
"city": "San Antonio",
"contacts": [
{
"email": null,
"name": null,
"phone": "210-545-0404",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jeffrey Rosenbloom",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Alamo ENT Associates",
"geoPoint": {
"lat": 29.42412,
"lon": -98.49363
},
"state": "Texas",
"status": null,
"zip": "78258-3227"
},
{
"city": "Richmond",
"contacts": [
{
"email": null,
"name": null,
"phone": "804-622-3768",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Michael Armstrong",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Richmond Ear Nose and Throat",
"geoPoint": {
"lat": 37.55376,
"lon": -77.46026
},
"state": "Virginia",
"status": null,
"zip": "23235"
}
]
},
"descriptionModule": {
"briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Randomized, double-blind, parallel group, placebo controlled",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": "Double-blind",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 510,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)",
"nctId": "NCT06338995",
"orgStudyIdInfo": {
"id": "18790",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Eli Lilly and Company",
"id": "J2T-MC-KGBU",
"link": null,
"type": "OTHER"
},
{
"domain": "EU CT Number",
"id": "2023-508760-29-00",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity"
},
{
"measure": "Mean CFBL in Endoscopic Nasal Polyp Score (NPS)"
}
],
"secondaryOutcomes": [
{
"measure": "Mean change in Opacification of Sinuses Measured by the Lund Mackay score (LMK)"
},
{
"measure": "Mean change in Forced Expiratory Volume in 1 Second (FEV1)"
},
{
"measure": "Mean CFBL in Severity of Loss of Smell"
},
{
"measure": "Mean CFBL in Postnasal Drip"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Eli Lilly and Company"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-10-25"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-11-22"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Interoperative wisdom tooth removal in conjunction with BSSO"
}
]
},
"conditionsModule": {
"conditions": [
"Impacted Third Molar Tooth",
"Osteotomy",
"Orthognathic Surgery",
"Mandibular Fractures"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Aalborg",
"contacts": null,
"country": "Denmark",
"facility": "Aalborg universitets hospital",
"geoPoint": {
"lat": 57.048,
"lon": 9.9187
},
"state": null,
"status": null,
"zip": "9000"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to investigate the hypothesis that there are none difference in the treatment result of orthognathic surgery on the lower jaw, with interoperative wisdom tooth removal rather than preoperative wisdom tooth removal. In patients with severe dental malocclusion combined with a dentofacial deformity. The main question it aims to answer are:• Is there a difference in the degree of complication and the patient's perception, with inter-operative wisdom tooth removal rather than pre-operative wisdom tooth removal.Participants will be will be divided into two groups, with one group having their wisdom teeth removed 6 months before their jaw moving surgery and the other group having their wisdom teeth removed in connection with their jaw moving surgery."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Randomized controlled trial with a test group and a control group.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 150,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Fracture Pattern Following Bilateral Sagittal Split Osteotomy With or Without Impacted Third Molars",
"nctId": "NCT06338982",
"orgStudyIdInfo": {
"id": "N-20230059",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Fracture pattern following BSSO with or without impacted third molars"
},
{
"measure": "Condylar segment position following BSSO with or without impacted third molars"
},
{
"measure": "Oral Health Impact Profile-14 (OHIP-14)"
},
{
"measure": "The Modified Dental Anxiety Scale (MDAS)"
},
{
"measure": "Short Form-36 (SF-36)"
},
{
"measure": "PROMs"
}
],
"secondaryOutcomes": [
{
"measure": "Length of the surgical procedure"
},
{
"measure": "Intraoperative bleeding"
},
{
"measure": "Frequency of intra- and postoperative complications"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Kimie Bols Østergaard"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-10-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Carbohydrate Restriction after a Gastric Bypass"
}
]
},
"conditionsModule": {
"conditions": [
"Obesity, Morbid",
"NASH",
"Ketosis",
"Keto Acidosis",
"Carbohydrate Metabolism Disorder"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Astana",
"contacts": [
{
"email": "[email protected]",
"name": "Oral Ospanov, PhD",
"phone": "7015287734",
"phoneExt": "+7",
"role": "CONTACT"
}
],
"country": "Kazakhstan",
"facility": "Oral Ospanov",
"geoPoint": {
"lat": 51.1801,
"lon": 71.44598
},
"state": "Aqmola",
"status": "RECRUITING",
"zip": "010000"
}
]
},
"descriptionModule": {
"briefSummary": "Background:Ketosis after bariatric surgery is a metabolic process that occurs when the body breaks down fat for energy because of not getting enough carbohydrates.Insufficient production of ketone bodies reduces the rate of weight loss, and excessive amounts of ketones can lead to ketoacidosis or liver failure in patients with nonalcoholic steatohepatitis (NASH).The investigators hypothesize that weight loss is directly related to calorie intake, and a significant reduction in carbohydrate content leads to increased ketosis and the risk of ketoacidosis.Objectives:The study aimed to compare the incidence of ketoacidosis and liver failure in patients with NASH with different intakes of carbohydrates in the early postoperative period after gastric bypass. In addition, the investigators want to find out how carbohydrate restriction will affect weight loss for up to 1 year."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 150,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis",
"nctId": "NCT06338969",
"orgStudyIdInfo": {
"id": "PostBariKetosis",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Cases of ketosis and incidence of ketoacidosis"
},
{
"measure": "Cases of liver failure"
}
],
"secondaryOutcomes": [
{
"measure": "Change in body mass index (Δ BMI)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "The Society of Bariatric and Metabolic Surgeons of Kazakhstan"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "LDL reduction therapy"
}
]
},
"conditionsModule": {
"conditions": [
"Coronary Artery Disease",
"Hyperlipidemias"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Seoul",
"contacts": [
{
"email": "[email protected]",
"name": "Ki Hong Choi, MD",
"phone": "82-2-3410-3419",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Korea, Republic of",
"facility": "Samsung Medical Center",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "For the management of low-density lipoprotein-cholesterol (LDL-C), some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in LDL-C levels. High-intensity or maximally tolerated intensity can be maintained without a target goal. However, the European guideline recommends less than 55 mg/dL of LDL-C after PCI."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 94189,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "19 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Lipid-PCI",
"briefTitle": "Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI",
"nctId": "NCT06338956",
"orgStudyIdInfo": {
"id": "Lipid-PCI",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "MACCE"
}
],
"secondaryOutcomes": [
{
"measure": "Cardiovascular death"
},
{
"measure": "Spontaneous myocardial infarction"
},
{
"measure": "Repeat revascularization"
},
{
"measure": "Ischemic stroke"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Samsung Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Echocardiography"
},
{
"name": "Questionnaire"
}
]
},
"conditionsModule": {
"conditions": [
"Heart Failure Preserved Ejection Fraction",
"Pregnancy Complications"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Moscow",
"contacts": [
{
"email": "[email protected]",
"name": "Olga Dzhioeva, MD, PhD",
"phone": "+79166141821",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Max Shperling, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Alexandr Mols",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Russian Federation",
"facility": "National Medical Research Center for Therapy and Preventive Medicine",
"geoPoint": {
"lat": 55.75222,
"lon": 37.61556
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease. Nowadays, the relationship of adverse pregnancy factors with the development of long-term cardiac pathology, in particular, HFpEF, has not been completely established. One of the most significant issue is studying the younger phenotype of women.The goal of this observational analytical cross-sectional study is to study the relationship of heart failure with a preserved ejection fraction in middle-aged women with adverse pregnancy outcomes in the history of pregnancy.Research question: is there an association between adverse pregnancy factors and the development of HF in middle-aged women?Objectives1. To assess the frequency of detection of APOs in the history of pregnancy in middle-aged women, depending on the presence or absence of HFpEF.2. To compare clinical and anamnestic data, morphological and functional parameters of the heart in middle-aged women with the presence and absence of HFpEF.3. To establish an association between APOs and the development of HFpEF in the long-term period in middle-aged women.4. To identify mediators between the presence of APOs and the development of HFpEF in middle-aged women.Study population - 45-60 year-old women with the history of pregnancy (\\>20 weeks) in the absence of low left ventricle ejection fraction (\\<50%)Primary endpoint: The prevalence of HFpEF in patients with the history of APOs."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "45 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "MAPO-HF",
"briefTitle": "Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction",
"nctId": "NCT06338943",
"orgStudyIdInfo": {
"id": "02-02/24",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "HFpEF incidence"
},
{
"measure": "APOs incidence"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "National Medical Research Center for Therapy and Preventive Medicine"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-18"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Remote monitoring"
}
]
},
"conditionsModule": {
"conditions": [
"Crohn Disease",
"Colitis, Ulcerative",
"Inflammatory Bowel Diseases"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Routine follow-up of patients with inflammatory bowel disease (IBD) under stable doses of maintenance therapy or no IBD-related therapy at all, consists of intensive monitoring with prescheduled outpatient visits every six or twelve months. However, many of these patients do not require additional interventions from the IBD specialist during these visits. In addition, patients in long-term remission, often request a less frequent follow-up in the hospital and in consequence a less frequent absence from school or work. In conclusion, these routinely follow-up visits might put unnecessary burden on both healthcare providers and IBD patients, as well as on healthcare resources.Until now, no clear standard was set for how to organize a remote monitoring programme that is feasible and safe in a large patient population. Despite the possible added value of remote monitoring for IBD patients on stable or no therapy and who are in remission, they are seldomly the targeted population in clinical trials analysing the effects of remote monitoring in IBD. Secondly, a significant reduction in outpatient clinic visits, is often not actively included in the programme, but more an outcome result. Finally, to compose a safe remote monitoring programme, subjective and objective parameters of disease activity should be collected.With the ROADMAP study, the main objective is to evaluate the safety and feasibility of remote monitoring in IBD patients that are stable on their current therapy or receive no IBD-related therapy. Secondly, a health economic evaluation will be conducted. Patients will be randomised to either the remote monitoring group or control group. The remote monitoring group will visit the outpatient clinic after two years. During this two-year period, patients will be monitored remotely via three-monthly questionnaires (PRO-2, IBD disk, WPAI, EQ-5D-5L) and faecal calprotectin measures. An IBD nurse will evaluate all incoming data and act in case of red flags."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 456,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ROADMAP",
"briefTitle": "Remote Monitoring of Patients With an Inflammatory Bowel Disease Under no or Maintenance Therapy",
"nctId": "NCT06338930",
"orgStudyIdInfo": {
"id": "ROADMAP",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Patient safety measured as the number of patients not requiring unplanned IBD related hospital visits (outpatient clinic, emergency department, hospitalization, or surgery) or rescue therapy with steroids within two years."
}
],
"secondaryOutcomes": [
{
"measure": "Costs and cost savings for hospital, RIZIV, employer, patient, … in the intervention group versus the control group."
},
{
"measure": "Time saving for patients in the intervention group versus the control group will be measured using a \"timing questionnaire\"."
},
{
"measure": "Number of telephone/email contacts with the IBD team within one year and within two years."
},
{
"measure": "Number of contacts with the general practitioner for IBD related reasons within one year and within two years."
},
{
"measure": "Absence at work or school within one year and within two years in the intervention group versus the control group will be measured using the WPAI IBD questionnaire."
},
{
"measure": "Quality of life in the intervention group versus the control group will be measured using the European Quality of Live Five Dimension Five Level Scale."
},
{
"measure": "Number of patients refusing to participate in this trial and the reason why."
},
{
"measure": "Reasons to stop remote monitoring."
},
{
"measure": "Patient's compliance, measured via missing data in the intervention versus the control group"
},
{
"measure": "Satisfaction with the program in the intervention group."
},
{
"measure": "System usability in the intervention group."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Universitaire Ziekenhuizen KU Leuven"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-03-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03-02"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Vigorous-intensity physical activity program"
}
]
},
"conditionsModule": {
"conditions": [
"Mental Health Issue"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Vic",
"contacts": null,
"country": "Spain",
"facility": "University of Vic",
"geoPoint": {
"lat": 41.93012,
"lon": 2.25486
},
"state": "Barcelona",
"status": null,
"zip": "08500"
}
]
},
"descriptionModule": {
"briefSummary": "People with severe mental illness have unhealthy lifestyles and habits, such as sedentary behavior and physical inactivity. Which are associated with a higher prevalence of premature mortality and chronic comorbidities.The aim of this study is to evaluate the efficacy of a physical activity program, which pretends to increase the number of vigorous-intensity physical activity bouts in their daily life, as a habit, combining High Intensity Interval Training (HIIT) and Vigorous Intensity Life-Style Physical Activity (VILPA). Secondary aims are to evaluate the efficacy of the program on fitness, physical activity and sedentary behavior level and patron; depressive, mania and psychotic symptomatology, functionality and cognitive functioning; quality of life and mood."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "Participants in both groups are not aware of the existence of the other group. The health provider in the control group is aware of the existence of the intervention group but does not know which intervention is being carried out.",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "+MoveMENT",
"briefTitle": "Mental Health and Vigorous-intensity Physical Activity",
"nctId": "NCT06338917",
"orgStudyIdInfo": {
"id": "File 2022 DI 61",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Subjective perception of joy"
},
{
"measure": "Subjective perception of calm"
},
{
"measure": "Subjective perception of energy"
},
{
"measure": "Subjective perception of time spent"
},
{
"measure": "Subjective perception of the received information"
},
{
"measure": "Subjective perception of respect received"
}
],
"primaryOutcomes": [
{
"measure": "Psychotic symptomatology"
},
{
"measure": "Depression symptomatology"
},
{
"measure": "Depression severity"
},
{
"measure": "Mania symptomatology"
},
{
"measure": "Mania severity"
},
{
"measure": "Disability"
},
{
"measure": "Quality of life"
},
{
"measure": "Cognitive functioning"
},
{
"measure": "Mood"
}
],
"secondaryOutcomes": [
{
"measure": "Subjective physical activity patron"
},
{
"measure": "Subjective sedentary behaviour patron"
},
{
"measure": "Perception of physical fitness"
},
{
"measure": "Objective physical activity patron"
},
{
"measure": "Objective sedentary behavior patron"
},
{
"measure": "Cardiorespiratory endurance"
},
{
"measure": "Velocity"
},
{
"measure": "Agility"
},
{
"measure": "Lower limb strength"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "IRIS-CC"
},
{
"name": "AGAUR"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Vic - Central University of Catalonia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2026-01-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-09-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Problem-solving-based psychological intervention"
}
]
},
"conditionsModule": {
"conditions": [
"Suicide"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Santiago de Compostela",
"contacts": null,
"country": "Spain",
"facility": "Research Group on Mental Health and Psychopatology",
"geoPoint": {
"lat": 42.88052,
"lon": -8.54569
},
"state": "A Coruña",
"status": null,
"zip": "15782"
}
]
},
"descriptionModule": {
"briefSummary": "Suicide represents a personal tragedy and an enormous global public health problem. One of the most vulnerable groups is adults 50 years and older. Despite this stage of life is particularly amenable to the implementation of targeted suicide prevention strategies, we have few studies of the efficacy of psychological interventions, those that do exist have methodological limitations, and none were implemented in formats other than face-to-face, which limits their accessibility. There is a need for brief psychological interventions that can be administered in both face-to-face and remote formats, do not require long training periods, and are effective in different contexts: for example, problem-solving therapy. The main objective of this project is to evaluate the efficacy of a brief problem-solving psychological intervention for targeted suicide prevention in people aged 50 years and older, administered in face-to-face, conference call, and smartphone app formats. A randomized controlled trial will be performed. Participants will be recruited through healthcare centers in the Autonomous Community of Galicia (Spain). To be included, participants must: (a) be at least 50 years old, (b) reside in Galicia, and (c) present suicidal ideation. Subjects will be excluded if they: (a) present serious mental health or medical disorders; (b) have begun receiving psychological or psychopharmacological treatment in the previous two months or are participating in other suicide prevention research; (c) do not have an appropriate mobile device or sufficient fluency to communicate in Spanish, or have problems that make it impossible to participate; or (d) plan to move in the next 18 months. At pre-intervention information will be collected on sociodemographic, family, personal history, current suicide risk and other clinical variables. 212 participants will be randomly assigned to (1) a problem-solving-based psychological intervention delivered face-to-face (PSPI-FF; experimental group 1); (2) a problem-solving-based psychological intervention delivered via telephone conference call (PSPI-CC; experimental group 2); (3) a problem-solving-based psychological intervention delivered via a smartphone app (PSPI-A; experimental group 3); or (4) a usual care control group (UCCG). Participants in the experimental groups will complete the six sessions/modules of the interventions. Finally, subjects in all groups will be evaluated at post-intervention and 3, 6 and 12-month follow-ups."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 212,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "SOLPROSU50+",
"briefTitle": "Brief Problem-solving Intervention in Different Formats for the Prevention of Suicide in Adults Over 50",
"nctId": "NCT06338904",
"orgStudyIdInfo": {
"id": "PID2022-141225OB-I00",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Sociodemographic, familial, personal history, and current suicide risk variables"
}
],
"primaryOutcomes": [
{
"measure": "Change from baseline suicidal ideation to post-treatment (7 weeks), and follow-ups at 6 and 12 months."
},
{
"measure": "Change from baseline suicidal ideation to post-treatment (7 weeks), and follow-ups at 6 and 12 months."
}
],
"secondaryOutcomes": [
{
"measure": "Change from baseline hopelessness to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline anxiety and depressive symptoms to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline reasons for living to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline impulsivity to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline problem-solving skills to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline social support to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Change from baseline syndrome of clinical anger to post-treatment (7 weeks), and follow-ups at 6 and 12 months"
},
{
"measure": "Treatment adherence"
},
{
"measure": "Satisfaction with the service received"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Ministry of science and innovation of Spain"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Santiago de Compostela"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-05-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Main questionnaire"
},
{
"name": "Secondary questionnaire"
}
]
},
"conditionsModule": {
"conditions": [
"Familial Mediterranean Fever",
"Non-celiac Gluten Sensitivity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Palermo",
"contacts": [
{
"email": "[email protected]",
"name": "Pasquale Mansueto",
"phone": "00390916554815",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Pasquale Mansueto",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Antonio Carroccio",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Aurelio Seidita",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "University Hospital of Palermo",
"geoPoint": {
"lat": 38.13205,
"lon": 13.33561
},
"state": "Sicily",
"status": "RECRUITING",
"zip": "90127"
}
]
},
"descriptionModule": {
"briefSummary": "Familial Mediterranean Fever (FMF) is a chronic hereditary autoinflammatory disease caused by mutations in the MEditerranean FeVer (MEFV) gene which codes for pyrin. Dysfunction of this protein determines an inappropriate response to inflammatory stimuli. The clinical course of the disease is characterized by recurrent episodes of fever and inflammation of the serous membranes, which manifest with chest, abdominal and joint pain. Several studies suggest a possible association between acute FMF attacks and dietary triggers, including wheat. However, it is still unclear to what extent wheat is responsible for the reactivation of FMF and if, between one acute attack and another, patients with FMF experience other symptoms, both gastrointestinal and extraintestinal, characteristic of gluten/wheat sensitivity not linked to celiac disease or immunoglobulin E (IgE)-mediated wheat allergy (i.e. Non-Celiac Wheat Gluten/Sensitivity, NCGS/NCWS).Therefore, this study aims to evaluate the appearance of symptoms compatible with an acute attack of FMF following the ingestion of wheat or other foods, and the prevalence of self-perceived gluten/wheat sensitivity in patients with FMF."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "6 Months",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks",
"nctId": "NCT06338891",
"orgStudyIdInfo": {
"id": "ACPM34",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Prevalence of the self-perception of wheat as a potential trigger of acute attack in patients with familial Mediterranean fever (FMF)"
},
{
"measure": "Prevalence of the self-perception of other foods, other than wheat, as potential triggers of an acute attack in patients with FMF"
},
{
"measure": "Prevalence of self-reported NCGS/NCWS in patients with FMF"
}
],
"secondaryOutcomes": [
{
"measure": "Genetic differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Genetic differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Genetic differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Ethnic group differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Ethnic group differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Ethnic group differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Education level differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Education level differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Education level differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Working activity differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Working activity differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Working activity differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Gastrointestinal symptoms differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Gastrointestinal symptoms differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Gastrointestinal symptoms differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Extraintestinal symptoms differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Extraintestinal symptoms differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Extraintestinal symptoms differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Extraintestinal symptoms duration differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Extraintestinal symptoms duration differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Extraintestinal symptoms duration between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Gastrointestinal symptoms duration differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Gastrointestinal symptoms duration differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Gastrointestinal symptoms duration differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "FMF specific drugs intake differences between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "FMF specific drugs intake differences between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "FMF specific drugs intake differences between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Differences in number/year of FMF attacks between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Differences in number/year of FMF attacks between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Differences in number/year of FMF attacks between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Differences in FMF specific drugs intake adherence between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Differences in FMF specific drugs intake adherence between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Differences in FMF specific drugs intake adherence between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Differences in marital status between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Differences in marital status between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Differences in marital status between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Differences in age at FMF diagnosis between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Differences in age at FMF diagnosis between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Differences in age at FMF diagnosis between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
},
{
"measure": "Differences in age at FMF symptom's onset between FMF patients who perceive a trigger effect of wheat and those who do not identify this specific food as a potential trigger of the disease flares."
},
{
"measure": "Differences in age at FMF symptom's onset between FMF patients who perceive a trigger effect of foods other than wheat and those who do not identify foods other than wheat as a potential trigger of disease flares."
},
{
"measure": "Differences in age at FMF symptom's onset between patients with FMF who self-report NCGS/NCWS and those who do not self-report it."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Palermo"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Heart Failure"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nancy",
"contacts": [
{
"email": "[email protected]",
"name": "Laura FILIPPETTI",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "CHRU de Nancy",
"geoPoint": {
"lat": 48.68439,
"lon": 6.18496
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This is a monocentric cohort study conducted in the cardiology department of Nancy hospital. The main purpose of the study is to document the global management strategy of patients hospitalized for heart failure and evaluate the association between patient's care and post-hospitalization outcome."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PATHWAY-HF",
"briefTitle": "PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes",
"nctId": "NCT06338878",
"orgStudyIdInfo": {
"id": "2023PI087",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "All-cause post-hospitalization mortality"
},
{
"measure": "Rehospitalization for heart failure"
}
],
"secondaryOutcomes": [
{
"measure": "Percentage of maximum dose of each cardiotropic treatment indicated in heart failure according to ESC recommendations"
},
{
"measure": "Influenza and pneumococcal vaccination status"
},
{
"measure": "Evolution of renal function"
},
{
"measure": "All-cause Rehospitalization"
},
{
"measure": "All-cause mortality"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Pr. Nicolas GIRERD"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Carbon dioxide"
},
{
"name": "Bupivacaine"
},
{
"name": "Oxycodone"
}
]
},
"conditionsModule": {
"conditions": [
"Laparoscopic Surgery"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This study aims to investigate the effect of varying insufflation pressures on post-operative pain and adequacy of surgical field visualization among patients undergoing laparoscopic surgery with a minimally invasive gynecologic surgeon."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "Patients and post-anesthesia care unit nurses will be masked.",
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 294,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Short Title: Standard vs. Lower Pressure Pneumoperitoneum",
"nctId": "NCT06338865",
"orgStudyIdInfo": {
"id": "Study00003146",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Maximum documented pain score in post-anesthesia care unit (PACU) (numerical rating scale, 0-10)"
}
],
"secondaryOutcomes": [
{
"measure": "First reported pain score in PACU (numerical rating scale, 0-10)"
},
{
"measure": "Last reported pain score in PACU prior to discharge (numerical rating scale, 0-10)"
},
{
"measure": "Inpatient morphine milligram equivalents"
},
{
"measure": "Total number of 5mg oxycodone pills taken in the 2 weeks following discharge"
},
{
"measure": "Need for insufflation pressure increase intra-operatively due to inadequate visualization"
},
{
"measure": "Operative time"
},
{
"measure": "Estimated blood loss"
},
{
"measure": "Intraoperative complications"
},
{
"measure": "Conversion to laparotomy"
},
{
"measure": "Postoperative length of stay"
},
{
"measure": "Surgeon-reported adequacy of assigned insufflation pressure"
},
{
"measure": "Need for adjustment of insufflation pressure"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cedars-Sinai Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Socio demographic and evaluation questionnaires"
}
]
},
"conditionsModule": {
"conditions": [
"Genital Prolapse"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cairo",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of physical therapy cairo university",
"geoPoint": {
"lat": 30.06263,
"lon": 31.24967
},
"state": null,
"status": null,
"zip": "37617692"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study will be to detect if there is awareness of gynecologists about the role of physical therapy in genital prolapse.Physical therapy plays an important role in assessment, prevention and treatment of pelvic floor dysfunction and genital prolapse, it helps to stimulate and strength pelvic floor muscle.Physical therapy treatments for the pelvic floor may include bladder training, pelvic floor muscles training with or without biofeedback, vaginal cones, electro stimulation or other adjuncts to training."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 370,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "44 Years",
"minimumAge": "29 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Awareness of Gynaecologists About Role of Physical Therapy in Genital Prolapse",
"nctId": "NCT06338852",
"orgStudyIdInfo": {
"id": "4347",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Socio demographic and evaluation questionnaires"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cairo University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-07-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-06-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-03-03"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Akhtubinsk",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 48.27955,
"lon": 46.17217
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Astrakhan",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 46.34968,
"lon": 48.04076
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Beslan",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 43.19217,
"lon": 44.54313
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Izhevsk",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 56.84976,
"lon": 53.20448
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Kaluga",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 54.5293,
"lon": 36.27542
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Krasnodar",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 45.04484,
"lon": 38.97603
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Rostov-on-Don",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 47.23135,
"lon": 39.72328
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Smolensk",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 54.7818,
"lon": 32.0401
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Vladimir",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 56.13655,
"lon": 40.39658
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Vladivostok",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 43.10562,
"lon": 131.87353
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Volgograd",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 48.71939,
"lon": 44.50183
},
"state": null,
"status": "RECRUITING",
"zip": null
},
{
"city": "Yaroslavl",
"contacts": null,
"country": "Russian Federation",
"facility": "Research Site",
"geoPoint": {
"lat": 57.62987,
"lon": 39.87368
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "A multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis (ATTR) cardiomyopathy (CM) in Russian patients with heart failure with preserved ejection fraction (HFpEF) in real clinical practice.The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who are participating/participated in the PRIORITY-CHF study and have HFpEF. Those patients who have a high suspicion of having ATTR-CM and provided informed consent will be invited to participate in the prospective phase. The prospective phase will consist of three visits, during which a routine comprehensive cardiologic evaluation in order to confirm or exclude ATTR-CM diagnosis will be performed. In patients with confirmed ATTR-CM the material for genetic testing will be collected in order to specify the type of ATTR-amyloidosis"
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "OTHER"
},
"enrollmentInfo": {
"count": 6000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "TETRAMER",
"briefTitle": "Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia",
"nctId": "NCT06338839",
"orgStudyIdInfo": {
"id": "D8450R00006",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Prevalence of ATTR-CM in patients with HFpEF in routine clinical practice in the Russian Federation"
}
],
"secondaryOutcomes": [
{
"measure": "demographic and clinical characteristics, and test results"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "AstraZeneca"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-11-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-28"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI"
},
{
"name": "Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)"
}
]
},
"conditionsModule": {
"conditions": [
"HIV Infections",
"HBV Coinfection"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "Interventional, sequential, Phase IIA equivalent, multicenter, open-label, randomized, non-comparative study evaluating, for 96 weeks, the safety in terms of HBV virological control of 2 antiviral therapy relief strategies, in HIV-1 and HBV co-infected patients with prolonged virological success (undetectable HIV-1 and HBV viral loads for ≥ 2 years) and on unmodified antiviral therapy for ≥ 1 year.Participants will be randomized 1:2:2 into 3 parallel arms:* Arm 1 (reference arm): Continuation of continuous (7 days/week) triple antiviral therapy including TDF or TAF* Arm 2 (T4): Relief from previous triple antiviral therapy (containing TDF or TAF) on 4 out of 7 consecutive days* Arm 3 (B7): Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR). The choice of dual therapy is left to the discretion of the investigator.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 140,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "BI-LIGHT",
"briefTitle": "Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses",
"nctId": "NCT06338826",
"orgStudyIdInfo": {
"id": "ANRS0250s-BI-LIGHT",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The proportion of participants with HBV virological failure at 96 weeks."
}
],
"secondaryOutcomes": [
{
"measure": "• HBV virological success rate at 48 weeks"
},
{
"measure": "• HIV virological success rate at 48 and 96 weeks"
},
{
"measure": "• Time to virological failure (rebound HBV and/or HIV viral load)"
},
{
"measure": "• The rate of participants with at least one HBV viral load blip until W48 and until W96"
},
{
"measure": "• Selection of HBV resistance mutations at the time of virological failure"
},
{
"measure": "• Incidence of grade 3 or higher adverse events of grade 3 or higher, incidence of adverse events and incidence of strategy discontinuation of the strategy at W48 and W96"
},
{
"measure": "• Evolution of CD4 from W0 to W48 and W96"
},
{
"measure": "• Evolution of total cholesterol from W0 to W48 and W96"
},
{
"measure": "• Evaluation of the adherence by self-reported questionnaire"
},
{
"measure": "• Evaluation of quality of life using the Pro-Qol self-questionnaire"
},
{
"measure": "Evolution of CD8 T lymphocytes from W0 to W48 and W96"
},
{
"measure": "Evolution of the CD4/CD8 ratio from W0 to W48 and W96"
},
{
"measure": "Evolution of LDL-c from W0 to W48 and W96"
},
{
"measure": "Evolution of HDL-c from W0 to W48 and W96"
},
{
"measure": "Evolution of triglycerides from W0 to W48 and W96"
},
{
"measure": "Evolution of fasting blood sugar from W0 to W48 and W96"
},
{
"measure": "HBV virological success rate at 96 weeks between arms"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "ANRS, Emerging Infectious Diseases"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-02-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-02-28"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Digital Manometry"
}
]
},
"conditionsModule": {
"conditions": [
"Ileus"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": null,
"country": "Turkey",
"facility": "Ankara City Hospital",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": null,
"zip": "06100"
}
]
},
"descriptionModule": {
"briefSummary": "Although many measurement techniques have been tried for intra-abdominal pressure, the Kron technique is currently the gold standard method. However, the search for other methods continues due to its long application time, the need for more equipment, and impracticality. Consequently, the investigators sought to investigate a quicker and more accessible method suitable for successful intra-abdominal pressure measurement in the emergency department. This study aimed to compare intra-abdominal pressure measurements in patients diagnosed with ileus using a digital manometer and the Kron Technique."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "99 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus",
"nctId": "NCT06338813",
"orgStudyIdInfo": {
"id": "Merve Unutmaz",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Digital manometer measuring for Intraabdominal Pressure"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ankara City Hospital Bilkent"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-02-22"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-10-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "One session exposure with Virtual Reality"
}
]
},
"conditionsModule": {
"conditions": [
"Anxiety Disorders",
"Exposure",
"Social Anxiety Disorder"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this study is to evaluate one session with exposure with Virtual Reality (VR) in in children and adolescents, aged 8-18 years with an anxiety disorder. The main questions it aims to answer are:1. What are the expectations of children and adolescents and therapists with VR exposure?2. What is the acceptability of the VR session (positive and negative effects)?3. What are possible working mechanisms of VR exposure? During ongoing treatment, participants will receive a session of exposure with VR."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "During ongoing treatment for their anxiety disorder 30 children and adolescents (8-18 years) with an anxiety disorder will receive a session of exposure with VR. Before the session expectations of VR exposure will be assessed. Before and after the session willingness to participate in exposure in vivo will be measured. During the session anxiety, idiosyncratic expectations, and self-efficacy are measured. After the session, positive effects, experiences, and negative side effects will be asked for.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "18 Years",
"minimumAge": "8 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "One Session Virtual Reality During Ongoing Treatment for Anxiety: Feasibility in Children and Adolescents",
"nctId": "NCT06338800",
"orgStudyIdInfo": {
"id": "PSY-2324-S-0134",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Willingness to participate in exposure in vivo"
}
],
"secondaryOutcomes": [
{
"measure": "Idiosyncratic expectations"
},
{
"measure": "Anxiety"
},
{
"measure": "Expectations of Virtual Reality"
},
{
"measure": "Acceptability"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Accare"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "FeSC"
}
]
},
"conditionsModule": {
"conditions": [
"Iron Deficiencies"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study aims to assess the efficacy of a novel iron supplement in improving iron status, gut microbiome, and exercise performance in endurance-trained females."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "17 Years",
"minimumAge": "14 Years",
"sex": "FEMALE",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Novel Iron-Based Supplement for Athletes Aged 14-17",
"nctId": "NCT06338787",
"orgStudyIdInfo": {
"id": "23-0826.2",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Gastrointestinal Symptoms 1"
},
{
"measure": "Gastrointestinal Symptoms 2"
},
{
"measure": "Sleepiness"
},
{
"measure": "Stress and Recovery"
}
],
"primaryOutcomes": [
{
"measure": "Iron Status"
},
{
"measure": "Hemoglobin"
},
{
"measure": "Lower Gut microbiome"
}
],
"secondaryOutcomes": [
{
"measure": "Exercise Capacity"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Mitacs"
},
{
"name": "Natural Sciences and Engineering Research Council, Canada"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Calgary"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-09"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Cognitive training"
},
{
"name": "Exercise"
}
]
},
"conditionsModule": {
"conditions": [
"Physical Inactivity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Iowa City",
"contacts": [
{
"email": "[email protected]",
"name": "Michelle W Voss, PhD",
"phone": "319-335-2057",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Ruthina Malone",
"phone": "319-335-2407",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Michelle Voss, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Psychological and Brain Sciences Building",
"geoPoint": {
"lat": 41.66113,
"lon": -91.53017
},
"state": "Iowa",
"status": null,
"zip": "52242"
},
{
"city": "Boston",
"contacts": [
{
"email": "[email protected]",
"name": "Charles Hillman, PhD",
"phone": "617-373-8342",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Virginia Davis",
"phone": "617-373-3448",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Charles Hillman, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Arthur F Kramer, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Center for Cognitive and Brain Health",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02115"
}
]
},
"descriptionModule": {
"briefSummary": "This trial is designed to develop and test the efficacy of cognitive training strategies to improve self-regulatory capacities for middle-aged adults to adopt and sustain a physically active lifestyle. The main questions it aims to answer are:* Can cognitive training designed to improve cognitive control improve physical activity adherence?* What are the psychological, physiological, cognitive, and sociodemographic factors that affect the impact of cognitive control on physical activity adherence?Participants will* Complete a 6-week home-based, computerized cognitive training program* Complete a 6-week home-based, aerobic exercise training program with supervision of a health coach and trainer* Complete a 6-week home-based, aerobic exercise training program prescribed by a health coach and trainer* Visit the laboratory before and after cognitive training, and before and after physical training, to complete assessments of cognition and aerobic fitness"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Six week parallel group intervention, followed by a 12 week exercise program.",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 264,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "BOOST",
"briefTitle": "Cognitive Control to Boost Physical Activity Adherence",
"nctId": "NCT06338774",
"orgStudyIdInfo": {
"id": "202310129",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "R33AG078041",
"link": "https://reporter.nih.gov/quickSearch/R33AG078041",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Physical Activity Adherence"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Northeastern University"
},
{
"name": "National Institute on Aging (NIA)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Iowa"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Smoking cessation"
},
{
"name": "Switching to E-cigarette"
}
]
},
"conditionsModule": {
"conditions": [
"Coronary Artery Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Seoul",
"contacts": [
{
"email": "[email protected]",
"name": "Ki Hong Choi, MD",
"phone": "82-2-3410-3419",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Korea, Republic of",
"facility": "Samsung Medical Center",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) remains uncertain."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 17442,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "20 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "E-cig-PCI",
"briefTitle": "Switching to E-cigarette After PCI",
"nctId": "NCT06338761",
"orgStudyIdInfo": {
"id": "E-cigarette PCI",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "MACE"
}
],
"secondaryOutcomes": [
{
"measure": "Cardiovascular death"
},
{
"measure": "All-cause death"
},
{
"measure": "Spontaneous myocardial infarction"
},
{
"measure": "Repeat revascularization"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Samsung Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode"
}
]
},
"conditionsModule": {
"conditions": [
"Continuous Glucose Monitoring"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cleveland",
"contacts": [
{
"email": "[email protected]",
"name": "Kimberly Jenkins",
"phone": "216-445-4791",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Kimberly Jenkins",
"phone": "(216) 445-4791",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "The Cleveland Clinic Foundation",
"geoPoint": {
"lat": 41.4995,
"lon": -81.69541
},
"state": "Ohio",
"status": null,
"zip": "44195"
}
]
},
"descriptionModule": {
"briefSummary": "This is a prospective longitudinal study to study the agreement between a continuous glucose monitoring system (CGMS) versus current blood glucose monitoring. Subjects in this study will have their blood glucose measured regularly every 1-3 hours with current methods in the Cardiovascular Intensive Care Unit (CVICU), and by Point of Care (POC) fingerstick glucose using the Accucheck Inform II on the regular floors, and the CGMS reading at the same time will be captured. Subjects will have measurements taken throughout their stay in the CVICU and on the regular floors. Agreement and correlation between systems, as well as errors, will be calculated."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Patients undergoing heart surgery at the Cleveland Clinic (main campus) who would normally be tested for high sugar levels by poking a finger and using a test strip.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "The study will involve using blinded Dexcom G7 continuous glucose monitoring (CGM) devices",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 28,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "DexcomG7",
"briefTitle": "Accuracy of the Dexcom G7 Continuous Glucose Monitoring System Following Cardiac Surgery",
"nctId": "NCT06338748",
"orgStudyIdInfo": {
"id": "24-157",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from arterial blood gas (ABG) or peripheral/central venous catheter or fingerstick point of care (POC) while patients are in the CVICU"
},
{
"measure": "Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from fingerstick POC glucose when patients are on the regular floors"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "DexCom, Inc."
}
],
"leadSponsor": {
"class": "OTHER",
"name": "The Cleveland Clinic"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Ultra-High Frequency Ultrasound scan of minor salivary glands"
}
]
},
"conditionsModule": {
"conditions": [
"Sjogren's Syndrome"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pisa",
"contacts": [
{
"email": "[email protected]",
"name": "Rossana Izzetti",
"phone": "+39050993037",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Rossana Izzetti",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "University of Pisa",
"geoPoint": {
"lat": 43.70853,
"lon": 10.4036
},
"state": null,
"status": "RECRUITING",
"zip": "56126"
}
]
},
"descriptionModule": {
"briefSummary": "Patients diagnosed with a diagnosis of Sjogren's syndrome performed according to the ACR/EULAR criteria will be included in the study. Sjogren's syndrome diagnosis will be performed following a complete diagnostic work-up involving rheumatologic assessment, glandular functional tests, and blood testing for anti-Ro(SSA) antibodies. Conventional ultrasonography of major salivary glands and ultra-high frequency ultrasonography (70 MHz) of minor salivary glands will be performed, and the scans assessed using the Outcome Measures in Rheumatology (OMERACT) scoring system (Score 0 normal glandular tissue, Score 1 mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis. Focus Score will be assessed following biopsy of minor salivary glands."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 800,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "UltraSjögren",
"briefTitle": "Ultra-High Frequency Ultrasonography in Sjögren's Syndrome",
"nctId": "NCT06338735",
"orgStudyIdInfo": {
"id": "14540",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "OMERACT score"
},
{
"measure": "Correspondence between ultrasonography and histology"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Pisa"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2016-01-11"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Making it Work Systemic Sclerosis"
}
]
},
"conditionsModule": {
"conditions": [
"Scleroderma, Systemic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Albuquerque",
"contacts": [
{
"email": "[email protected]",
"name": "Janet L Poole, PhD",
"phone": "505-272-8276",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "University of New Mexico",
"geoPoint": {
"lat": 35.08449,
"lon": -106.65114
},
"state": "New Mexico",
"status": "RECRUITING",
"zip": "87131-0001"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this clinical trial is to see if an online intervention program for people with Systemic Sclerosis (scleroderma) helps keep people in the workforce and increase self-confidence in dealing with challenges at work. The program is called Making it Work Systemic Sclerosis.Researchers will compare a group who gets the program to a group who will get the program at a later point in time (wait list control group) to see if self-confidence in dealing with work challenge gets better.People in the Making it Work group will complete questionnaires and attend one 2 hour meetings each week for 5 weeks and meet with an occupational therapist and vocational counselor. People in the wait list control group will complete the questionnaires and participate in the program at a later point in time."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Intervention receives the Making it work program Wait list Control receives usual care but will be offered the program after the intervention groups finish",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "People will know what group they are in when they are invited to attend the intervention sessions",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "67 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Making it Work Program for Systemic Sclerosis",
"nctId": "NCT06338722",
"orgStudyIdInfo": {
"id": "23-397",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Job Related Self-efficacy Scale"
},
{
"measure": "Job Self-Efficacy Scale"
}
],
"secondaryOutcomes": [
{
"measure": "Work Productivity and Activity Impairment Questionnaire Specific Health Problem Subscale"
},
{
"measure": "The Work Instability Scale"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of New Mexico"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-08"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "BariClip® Device Treatment"
}
]
},
"conditionsModule": {
"conditions": [
"Overweight and Obesity"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Overweight and obesity are at epidemic proportions in the world population as well as in the United States, where nearly 42% of the adult population(1) is considered to meet the definition of obesity, namely a body mass index (\"BMI\") ≥ 30 kg/m2. Well-established links between obesity and increased morbidities and mortality make treatment of the utmost importance; however, there continues to be a significant unmet need for more effective treatments for obesity. Bariatric surgery is recognized as an effective treatment for obese patients, particularly in more severe cases where surgical restriction of the stomach's capacity and outlet size are considered necessary. The BariClip® is a laparoscopically implanted device for treatment of obesity and serves as an alternative to current existing technology for use in bariatric surgery. The BariClip® is a medical device, non-adjustable, resembling a clip that is placed parallel to the greater curvature of the stomach, causing restriction of the gastric lumen in a vertical fashion. This multi-center, randomized, moderate-lifestyle (program of diet and exercise) controlled pivotal study of the BariClip® device is intended to gather data to objectively support its safety and effectiveness for the treatment of obesity in adults and to ultimately support marketing authorization of this device as a viable alternative to existing bariatric surgical procedures. Specifically, this study aims to look at efficacy of the BariClip® device with regards to weight loss metrics and secondary health metrics and safety of the BariClip® device with regards to serious adverse events."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 165,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "22 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Clinical Study Protocol for the Assessment of Safety and Efficacy of the BARICLIP®",
"nctId": "NCT06338709",
"orgStudyIdInfo": {
"id": "11-002",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Incidence of Serious Adverse Events (SAEs)"
}
],
"primaryOutcomes": [
{
"measure": "Achieving ≥ 5% total body weight loss (TBWL) in 50% of treated subjects"
},
{
"measure": "Achieving ≥ 5% superiority margin for weight loss in the treated group as compared to the control group"
}
],
"secondaryOutcomes": [
{
"measure": "Weight and Height will be combined to report BMI in kg/m^2"
},
{
"measure": "Blood Pressure (BP) in mmHg, both systolic and diastolic"
},
{
"measure": "Diagnosis and/or Change in Severity of Diabetes Mellitus (DM)"
},
{
"measure": "Weight in kilograms"
},
{
"measure": "Height in meters"
},
{
"measure": "Waist Circumference in centimeters"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "NAMSA"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Advanced Bariatric Technology"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-09"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "No intervention"
}
]
},
"conditionsModule": {
"conditions": [
"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bangkok",
"contacts": [
{
"email": null,
"name": "Sarinya Puwanant, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Sarinya Puwanant, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Faculty of Medicine at Chulalongkorn University",
"geoPoint": {
"lat": 13.75398,
"lon": 100.50144
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Bangkok",
"contacts": [
{
"email": null,
"name": "Teerapat Yingchoncharoen, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Teerapat Yingchoncharoen, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Faculty of Medicine Ramathibodi hospital, Mahidol University",
"geoPoint": {
"lat": 13.75398,
"lon": 100.50144
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Bangkok",
"contacts": [
{
"email": null,
"name": "Kanchalaporn Jirataiporn, B.N.S",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Srisakul Chirakarnjanakorn, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Adisak Maneesai, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Porntera Sethalao, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Faculty of Medicine Siriraj Hospital, Mahidol University",
"geoPoint": {
"lat": 13.75398,
"lon": 100.50144
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Bangkok",
"contacts": [
{
"email": null,
"name": "Hutsaya Prasitdumrong, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Hutsaya Prasitdumrong, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Phramongkutklao Hospital",
"geoPoint": {
"lat": 13.75398,
"lon": 100.50144
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Chiang Mai",
"contacts": null,
"country": "Thailand",
"facility": "Faculty of Medicine Chiang Mai University",
"geoPoint": {
"lat": 18.79038,
"lon": 98.98468
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Khon Kaen",
"contacts": [
{
"email": null,
"name": "Vichai Senthong, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Vichai Senthong, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Queen Sirikit Heart Center of The Northeast",
"geoPoint": {
"lat": 16.44671,
"lon": 102.833
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Pathum Thani",
"contacts": [
{
"email": null,
"name": "Adisai Buakhamsri, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Adisai Buakhamsri, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Thailand",
"facility": "Faculty of Medicine, Thammasat University",
"geoPoint": {
"lat": 14.01346,
"lon": 100.53049
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Songkhla",
"contacts": null,
"country": "Thailand",
"facility": "Prince of Songkla University",
"geoPoint": {
"lat": 7.19882,
"lon": 100.5951
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 105,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Thailand ATTR-CM Registry",
"nctId": "NCT06338696",
"orgStudyIdInfo": {
"id": "COA-CREC070/2023",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Rate of death"
},
{
"measure": "Rate of heart failure hospitalization"
}
],
"secondaryOutcomes": [
{
"measure": "Transthyretin (ATTR) amyloidosis medication"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Pfizer"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Mahidol University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-01"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Olanzapine 2.5 MG"
},
{
"name": "Standard anti-tumor treatment"
},
{
"name": "Nutritional advice"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Cancer",
"Olanzapine",
"Progression Free Survival"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Xining",
"contacts": [
{
"email": "[email protected]",
"name": "Qiuxia Dong, Dr",
"phone": "0971-8267613",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Qinghai Red Cross Hospital",
"geoPoint": {
"lat": 36.62554,
"lon": 101.75739
},
"state": "Qinghai",
"status": "RECRUITING",
"zip": "810000"
}
]
},
"descriptionModule": {
"briefSummary": "This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 230,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer",
"nctId": "NCT06338683",
"orgStudyIdInfo": {
"id": "QRCH-2024001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Comparing the difference in Median PFS between the two groups"
}
],
"secondaryOutcomes": [
{
"measure": "Comparing the difference in Median OS between the two groups"
},
{
"measure": "Comparing the difference in ORR between the two groups"
},
{
"measure": "Comparing the difference in the incidence of ≥3% weight loss between the two groups"
},
{
"measure": "Comparing the difference in BMI between the two groups"
},
{
"measure": "Comparing the difference in the improvement in other symptoms (appetite, nausea, fatigue, insomnia) between the two groups"
},
{
"measure": "Comparing the difference in Quality of life in the overall stage between the two groups"
},
{
"measure": "neutrophil-to-lymphocyte ratio"
},
{
"measure": "platelet-to-lymphocyte ratio"
},
{
"measure": "C-reactive protein (CRP) concentration"
},
{
"measure": "concentration of albumin"
},
{
"measure": "Level of interleukin (IL)-6 and IL-8"
},
{
"measure": "Comparing the difference in the side effects of olanzapine treatment between the two groups"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Qinghai Red Cross Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-03-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-20"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Cochlear Osia 3 Sound Processor"
},
{
"name": "Cochlear™ Osia® 2 Sound Processor"
}
]
},
"conditionsModule": {
"conditions": [
"Hearing Loss, Mixed Conductive-Sensorineural",
"Hearing Loss, Conductive"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Melbourne",
"contacts": [
{
"email": "[email protected]",
"name": "Robert Cowan",
"phone": "+61418780198",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Australia",
"facility": "The HEARing CRC",
"geoPoint": {
"lat": -37.814,
"lon": 144.96332
},
"state": "Victoria",
"status": null,
"zip": "3053"
}
]
},
"descriptionModule": {
"briefSummary": "This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Within-subject",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 12,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "RECONNECT",
"briefTitle": "Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users",
"nctId": "NCT06338670",
"orgStudyIdInfo": {
"id": "CLTD5839",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change (within subject) in speech reception threshold in noise with fixed noise level at 65 dB SPL"
},
{
"measure": "Change (within subject) in word recognition score in quiet measured at 65 dB SPL"
},
{
"measure": "Change (within subject) in aided thresholds in sound field measured at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz"
},
{
"measure": "Change (within subject) in the subjective rating of different aspects of sound when listening to sound clips"
},
{
"measure": "Percentage of participants who preferred Osia 3 over Osia 2 sound processor"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Avania"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Cochlear"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-11-22"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-11-22"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-08"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Biospecimen Collection"
},
{
"name": "Computed Tomography"
},
{
"name": "Magnetic Resonance Imaging"
},
{
"name": "PEOX-based Polymer Encapsulated Paclitaxel FID-007"
},
{
"name": "Tumor Resection"
}
]
},
"conditionsModule": {
"conditions": [
"Head and Neck Squamous Cell Carcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Los Angeles",
"contacts": [
{
"email": "[email protected]",
"name": "Sandy Tran, MS",
"phone": "323-865-0451",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jacob S. Thomas, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Los Angeles General Medical Center",
"geoPoint": {
"lat": 34.05223,
"lon": -118.24368
},
"state": "California",
"status": null,
"zip": "90033"
},
{
"city": "Los Angeles",
"contacts": [
{
"email": "[email protected]",
"name": "Sandy Tran, MS",
"phone": "323-865-0451",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jacob S. Thomas, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "USC / Norris Comprehensive Cancer Center",
"geoPoint": {
"lat": 34.05223,
"lon": -118.24368
},
"state": "California",
"status": null,
"zip": "90033"
}
]
},
"descriptionModule": {
"briefSummary": "This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 10,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer",
"nctId": "NCT06338657",
"orgStudyIdInfo": {
"id": "7H-23-5",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "CTRP (Clinical Trial Reporting Program)",
"id": "NCI-2024-01367",
"link": null,
"type": "REGISTRY"
},
{
"domain": "USC / Norris Comprehensive Cancer Center",
"id": "7H-23-5",
"link": null,
"type": "OTHER"
},
{
"domain": null,
"id": "P30CA014089",
"link": "https://reporter.nih.gov/quickSearch/P30CA014089",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Evaluate the phenotypical and functional changes of different T cell subsets within the tumor microenvironment after treatment with FID-007"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of adverse events (AEs)"
},
{
"measure": "Major pathologic response rate"
},
{
"measure": "Complete pathologic response rate"
},
{
"measure": "Rate of locoregional recurrence"
},
{
"measure": "Rate of distant metastasis"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Cancer Institute (NCI)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Southern California"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-04-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Palbociclib"
}
]
},
"conditionsModule": {
"conditions": [
"Hormone-receptor-positive Breast Cancer",
"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
"Metastatic Breast Cancer"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of agents recently introduced in the clinic for the treatment of advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) BC. Palbociclib, ribociclib and abemaciclib have all been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency among other regulatory bodies"
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Palbociclib",
"briefTitle": "Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.",
"nctId": "NCT06338644",
"orgStudyIdInfo": {
"id": "HelwanUY",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "1-year Progression free survival (PFS)"
}
],
"secondaryOutcomes": [
{
"measure": "Neutropenia"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Helwan University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-09-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Diet"
}
]
},
"conditionsModule": {
"conditions": [
"Obesity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milano",
"contacts": [
{
"email": "[email protected]",
"name": "Alberto Battezzati, Prof",
"phone": "+390261911",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Istituto Auxologico Italiano, Città Studi ICANS",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "RECRUITING",
"zip": "20100"
},
{
"city": "Naples",
"contacts": [
{
"email": null,
"name": "Bruna Guida, Prof.",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Programma Infradipartimentale di Dietoterapia nel Trapianto e nell' Insufficienza Renale Cronica, DAI di Medicina Interna ad Indirizzo Specialistico, del Policlinico Federico II di Napoli",
"geoPoint": {
"lat": 40.85216,
"lon": 14.26811
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Overweight and obesity are increasingly prevalent worldwide. Weight excess increases the risk of in developing the metabolic syndrome, which is composed by a set of cardiometabolic risk factors such as abdominal adiposity, dyslipidemia, high blood pressure and elevated fasting glucose levels. Obesity and the metabolic syndrome are known to be risk factors for the development of chronic kidney disease. It is not clear however, whether they can be considered independent risk factors for impaired renal function and renal damage. Whereas obesity may represent an independent risk factor for renal damage, it is not clear yet if the contemporaneous presence of obesity and metabolic alterations is associated with an additional increase in the risk.It may be important to understand the relationship between obesity, metabolic syndrome and renal health, as treatment strategies may be different for the two metabolic phenotypes of obesity, i.e., metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) patients.The primary objective of this multicentre observational prospective study is to assess the relationship between metabolic phenotype and reduced renal function (glomerular filtration rate \\<90 ml/min/1.73m2 or microalbuminuria 30-300 mg/24h) in a population of 1000 patients with overweight or obesity.The secondary aim is to study the association between diet quality, consumption of ultra-processed foods and indicators of reduced renal function and renal damage."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "OB-KID",
"briefTitle": "Early Detection of Renal Abnormalities in Metabolically Healthy and Unhealthy Weight Excess\"",
"nctId": "NCT06338631",
"orgStudyIdInfo": {
"id": "43C301",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Glomerular filtration rate"
},
{
"measure": "Microalbuminuria"
},
{
"measure": "Glycemia"
},
{
"measure": "Body mass index"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Istituto Auxologico Italiano"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-08-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "liver treatment protocol"
}
]
},
"conditionsModule": {
"conditions": [
"NAFLD, Non-alcoholic Fatty Liver Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Huelva",
"contacts": [
{
"email": "[email protected]",
"name": "Javer Carrasco Sánchez, Dr",
"phone": "682289772",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Spain",
"facility": "Universitary Hospital Juan Ramón Jiménez",
"geoPoint": {
"lat": 37.26638,
"lon": -6.94004
},
"state": null,
"status": "RECRUITING",
"zip": "21005"
}
]
},
"descriptionModule": {
"briefSummary": "Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver. The beneficial effect of manual therapy for the treatment of viscera dysfunctions such as the stomach or colon is known. The objective of this study is to demonstrate the anti-inflammatory effects of visceral manual therapy in patients with metabolic liver disease associated with non-alcoholic fatty liver."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 42,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "OSTEO-EHMet",
"briefTitle": "Manual Therapy in Metabolic Liver Disease",
"nctId": "NCT06338618",
"orgStudyIdInfo": {
"id": "1532-N-23",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Hepatic steatosis index"
}
],
"secondaryOutcomes": [
{
"measure": "FIB-4 index"
},
{
"measure": "NAFLD-fibrosis index"
},
{
"measure": "HOMA index"
},
{
"measure": "TyG index"
},
{
"measure": "Change from baseline in algometry"
},
{
"measure": "Visual analogue Scale"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Seville"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-03"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "no intervention, observational study of AKI under CDK4/6 inhibitor treatment"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Breast Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Rotterdam",
"contacts": null,
"country": "Netherlands",
"facility": "Erasmus Medical Center",
"geoPoint": {
"lat": 51.9225,
"lon": 4.47917
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "CDK4/6 inhibitors have led to an improvement of both progression free survival (PFS) and overall survival (OS) in patients with advanced estrogen positive (ER+)/HER2- breast cancer when applied in the first or second line of treatment. Despite the advantages of CDK4/6 inhibitors, these medications can lead to adverse effects. One of the adverse events observed across all types of CDK4/6 inhibitors is an elevation in creatinine levels. An elevation in plasma creatinine during treatment with abemaciclib is not always indicative of a reduction in renal function; it can also be attributed to the inhibition of active tubular secretion of creatinine. This phenomenon is known as pseudo acute kidney injury (pseudo-AKI).The incidence of pseudo-AKI in patients using CDK4/6 inhibitors is currently unknown. A method to distinguish pseudo-AKI from AKI is measuring the level of an alternative filtration marker in blood, for example cystatin C. Cystatin C is also filtered at the glomerulus but not secreted intro the renal tubulus or reabsorbed into the bloodstream. Also, there is no affection by muscle mass or diet. In this study the investigators will explore the incidence of both AKI and pseudo-AKI in patients who are treated with CDK4/6 inhibitor treatment by assessing both creatinine and cystatin C in plasma."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "CYSTATINcDK4/6",
"briefTitle": "Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis",
"nctId": "NCT06338605",
"orgStudyIdInfo": {
"id": "MEC-2023-0715",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Pseudo-AKI in patients on CDK4/6 inhibitors"
}
],
"secondaryOutcomes": [
{
"measure": "Pseudo-AKI in patients on CDK4/6 inhibitors per drug"
},
{
"measure": "AKI in patients"
},
{
"measure": "Influencing factors cystatin C levels"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Erasmus Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-12-12"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "MyLungHealth"
},
{
"name": "DecisionPrecision+"
}
]
},
"conditionsModule": {
"conditions": [
"Lung Cancer",
"Lung Neoplasms/Diagnosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "New York",
"contacts": [
{
"email": "[email protected]",
"name": "Devin Mann, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Devin Mann, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "NYU Langone Health",
"geoPoint": {
"lat": 40.71427,
"lon": -74.00597
},
"state": "New York",
"status": "RECRUITING",
"zip": "10016"
},
{
"city": "Salt Lake City",
"contacts": [
{
"email": "[email protected]",
"name": "Kensaku Kawamoto, MD, PhD, MHS",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Kensaku Kawamoto, MD, PhD, MHS",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "University of Utah Health",
"geoPoint": {
"lat": 40.76078,
"lon": -111.89105
},
"state": "Utah",
"status": "RECRUITING",
"zip": "84112"
}
]
},
"descriptionModule": {
"briefSummary": "Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision making."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "This is a patient randomized trial that includes two sub-studies, with 2 arms each.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": null
},
"enrollmentInfo": {
"count": 42415,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "79 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "MyLungHealth",
"briefTitle": "The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale",
"nctId": "NCT06338592",
"orgStudyIdInfo": {
"id": "UUtah_00153806",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Study 1 primary outcome: Percentage of participants identified as eligible for LCS."
},
{
"measure": "Study 2 primary outcome: Percentage of participants for whom LDCT was ordered."
}
],
"secondaryOutcomes": [
{
"measure": "Study 1 secondary outcome: Percentage of participants for whom LDCT was ordered."
},
{
"measure": "Study 1 secondary outcome: Percentage of participants for whom LDCT was completed."
},
{
"measure": "Study 2 secondary outcome: Percentage of participants for whom LDCT was completed."
},
{
"measure": "Study 2 secondary outcome: Percentage of participants for whom LCS care gap was closed."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Utah"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-27"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-28"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Questionnaire"
}
]
},
"conditionsModule": {
"conditions": [
"Self Medication"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "The goal of this cross-sectional descriptive observational study is to assess the extent of self-medication among the crews of surface ships at the Toulon naval base. This study could include healthy volunteers, or participants with well-controlled chronic pathologies enabling them to be fit for embarkation, who are currently being deployed for at least 4 weeks on a surface ship at the naval base.Participants will tick and complete a questionnaire (between 15 and 30 minutes) after 4 consecutive weeks on the ship."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 800,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "AutoMMaN",
"briefTitle": "Overview of Self-medication Among French Navy Personnel",
"nctId": "NCT06338579",
"orgStudyIdInfo": {
"id": "2023PPRC04",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "IDRCB",
"id": "2023-A01763-42",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "percentage of patients who have self-medication"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Direction Centrale du Service de Santé des Armées"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Follow-up"
}
]
},
"conditionsModule": {
"conditions": [
"Ankle Fractures"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "The goal of this prospective, single-center observational study is to describe the functional outcome of the surgical procedure in patient who undergone transplanted centromedullary nailing in the septic setting.Patients will be asked to complete a questionnaire during follow-up consultations."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PROCLOU",
"briefTitle": "Prospective Follow-up of the Results of Nail Arthrodesis of the Ankle",
"nctId": "NCT06338566",
"orgStudyIdInfo": {
"id": "2021PPRC10",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "IDRCB",
"id": "2023-A01975-40",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "bony outcome of transcalcaneal nailing"
}
],
"secondaryOutcomes": [
{
"measure": "functional result of the procedure"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Direction Centrale du Service de Santé des Armées"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Placebo"
},
{
"name": "Semaglutide (Rybelsus®)"
}
]
},
"conditionsModule": {
"conditions": [
"Type 1 Diabetes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nashville",
"contacts": [
{
"email": "[email protected]",
"name": "Justin M Gregroy, MD, MSCI",
"phone": "(615) 322- 7427",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Tyler J Smith, DNP, APRN, FNP-C",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Justin M Gregory, MD, MSCI",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Vanderbilt University Medical Center",
"geoPoint": {
"lat": 36.16589,
"lon": -86.78444
},
"state": "Tennessee",
"status": "RECRUITING",
"zip": "37232"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under three different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is pre-teplizumab, followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "In this study, participants with stage 2 T1DM undergoing Teplizumab (TZIELD®) treatment will be randomly assigned to receive single doses of either a GLP-1Ra or a placebo. Three separate MMTT tests will be conducted to assess the effects on blood sugar levels, insulin function, and vascular health. The first test will occur before TZIELD® treatment and participants will receive a placebo at this MMTT. The other two tests will take place 3-5 months after TZIELD® treatment. In these post-treatment tests, the study team will 'cross over', or switch, the order in which participants receive the GLP-1Ra or placebo, with a minimum one-week gap to avoid overlap of effects. For example, a participant may take the GLP-1Ra then placebo or the placebo then the GLP-1Ra. In some cases, the investigator may allow participants who have already received TZIELD® treatment prior to joining the study to skip the pre-treatment test and proceed directly to the post-treatment tests.",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": "For applicable participants, a placebo will be given prior to a pre-TZIELD® meal test. For participants who have already received Teplizumab (TZIELD®) or those who are progressing to the 2 remaining study visits, a GLP-1Ra or placebo will be given in random orders at these two visits. The GLP-1Ra will only be given one time.",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 24,
"type": "ESTIMATED"
},
"phases": [
"EARLY_PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "50 Years",
"minimumAge": "12 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": "GLP-TEP",
"briefTitle": "GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab",
"nctId": "NCT06338553",
"orgStudyIdInfo": {
"id": "231620",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study"
},
{
"measure": "Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study"
},
{
"measure": "Determine the impact of GLP-1Ra on endothelial function in a pilot study"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Vanderbilt University Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2023-12-27",
"filename": "Prot_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": false,
"label": "Study Protocol",
"size": 567921,
"typeAbbrev": "Prot",
"uploadDate": "2024-03-01T16:04"
},
{
"date": "2024-02-21",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 2385304,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-01T15:15"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Black color of caries"
},
{
"name": "dark brown color of caries"
},
{
"name": "light brown color of caries"
},
{
"name": "yellow color of caries"
}
]
},
"conditionsModule": {
"conditions": [
"Relation of Caries Color"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Mansoura",
"contacts": null,
"country": "Egypt",
"facility": "Mansoura university",
"geoPoint": {
"lat": 31.03637,
"lon": 31.38069
},
"state": "Dakahlia",
"status": null,
"zip": "35511"
}
]
},
"descriptionModule": {
"briefSummary": "This study is to find the relation of caries color to caries severity and its microbial load in primary molars."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Group 1: Yellow caries color Group 2: dark brown caries color Group 3: light brown caries color Group 4: black caries color",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "7 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Relation of Caries Color to Caries Severity and Its Microbial Load",
"nctId": "NCT06338540",
"orgStudyIdInfo": {
"id": "A26020822",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Caries color related to history of pain"
},
{
"measure": "Caries color related to ICDAS"
},
{
"measure": "Caries color related to pulp exposed"
},
{
"measure": "Caries color related to microbial load"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Mansoura University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-01-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Aromatherapy"
},
{
"name": "No intervention"
}
]
},
"conditionsModule": {
"conditions": [
"Sleep Quality",
"Anxiety"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Weifang",
"contacts": [
{
"email": "[email protected]",
"name": "Shirong Fang, M.D.",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Weifang People's Hospital",
"geoPoint": {
"lat": 36.71,
"lon": 119.10194
},
"state": "Shangdong",
"status": null,
"zip": "261000"
}
]
},
"descriptionModule": {
"briefSummary": "The objective of this study was to investigate the effects of aromatherapy on sleep quality and anxiety in patients undergoing chemotherapy for breast cancer."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 90,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effects of Aromatherapy on Patients Undergoing Chemotherapy for Breast Cancer",
"nctId": "NCT06338527",
"orgStudyIdInfo": {
"id": "2024YX321",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Sleep quality"
},
{
"measure": "Anxiety"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Weifang Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-26"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Real dry needling"
},
{
"name": "Sham dry needling"
}
]
},
"conditionsModule": {
"conditions": [
"Myofascial Trigger Point Pain"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Back pain is commonly seen in the working-age population, with the peak occurrence around the age of 40. Its frequency does not increase with age and is not associated with age-related degenerative changes in the spine. Especially when the underlying cause is conditions such as myofascial pain syndrome (MPS), where regional muscle sensitivity in the rhomboid and trapezius areas is prominent, dry needling treatment has become increasingly popular and the subject of numerous studies in recent years. In the diagnosis of MPS, two valuable findings include the detection of a taut band upon palpation and the presence of trigger points in muscle fibers with mild finger pressure. The study we are planning involves a double-blind efficacy trial where real and sham dry needling procedures will be performed under ultrasound guidance, ensuring that both the patient and the evaluator are blinded. This study design has the potential to make a significant contribution to the literature in this field."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A two-group, sham-controlled, double-blind, prospective, randomized controlled trial",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "In the dry needling application, patients will be blinded to the groups they are randomized into. The evaluator will also be unaware of which group the patients belong to. The practitioner will perform the procedures in both groups using ultrasound guidance, targeting the standard trigger points in the painful dorsal trapezius and rhomboid muscles in the study group, and targeting subcutaneous fatty tissue in the same regions in the sham group.",
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome.",
"nctId": "NCT06338514",
"orgStudyIdInfo": {
"id": "KutahyaHSU-DRYNEEDLE-dorsalgia",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Visual Analog Scale"
},
{
"measure": "Patient-Specific Functional Scale"
},
{
"measure": "Pressure Pain Threshold Measurement"
}
],
"secondaryOutcomes": [
{
"measure": "What does Oswestry stand for? The Oswestry Disability Index (ODI)"
},
{
"measure": "The 12-item Short-Form Health Survey version 2 (SF-12v2)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Kutahya Health Sciences University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-25"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-25"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-25"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Specifical Functional Training Exercises"
}
]
},
"conditionsModule": {
"conditions": [
"Nervous System Diseases",
"Dehydration"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "Known as \"Thai boxing,\" Muay Thai utilizes a combination of upper limb strikes (such as punches and elbow strikes) as well as lower limb strikes (such as kicks and knee strikes), and is thus referred to as the \"art of eight limbs.\" It is practiced worldwide and is a prominent discipline in many mixed martial arts (MMA) training camps. In this sport, training load control involves monitoring and adjusting the quantity and intensity of training according to each athlete's capacity. In the context of combat sports, such as Muay Thai, heart rate variability (HRV) and assessment of body composition by bioelectrical impedance analysis can be used as tools to evaluate training responses. Additionally, HRV can also serve as a tool for assessing recovery after training or competition. If HRV does not return to baseline after training or competition, it may be a sign that the athlete is not fully recovered and may need more time to recuperate before returning to training or competition. Due to the absence of studies in the literature that have assessed a possible association between HRV and dehydration and rehydration processes in amateur Muay Thai athletes, it becomes essential to evaluate this correlation. Given the growing interest in practicing Muay Thai in gyms, assessing the sympathetic-vagal balance, body composition, and performance of these athletes becomes of utmost importance. Therefore, the aim of this study is to investigate the relationship between dehydration indicators, HRV parameters, and performance in the frequency speed kick test (FSKT). Participants will be assessed before and after an eight-week training program, conducted three times a week. Assessments will include resting HRV measurement and FSKT; in addition, bioimpedance will be used to estimate the body composition of participants pre- and post-training. It is expected that the results will reveal changes in HRV, performance, and body composition of the athletes after training."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 36,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "MALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Assessment of Heart Rate Variability, Performance and Dehydration in Muay Thai Athletes",
"nctId": "NCT06338501",
"orgStudyIdInfo": {
"id": "77325224.4.0000.5235",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "HRV during specifical physical test"
}
],
"secondaryOutcomes": [
{
"measure": "Correlation with BIA analysis, HRV and Specific Physical Test"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Centro Universitário Augusto Motta"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-30"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Real dry needling"
},
{
"name": "Sham dry needling"
}
]
},
"conditionsModule": {
"conditions": [
"Shoulder Pain"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Myofascial pain can be diagnosed by the presence of one or more myofascial trigger points (MTrPs), defined as hyperirritable spots in taut bands of skeletal muscle fibers palpable by hand. The treatment of myofascial pain primarily relies on the inactivation of MTrPs, often through manual pressure techniques or dry needling. In manual pressure techniques, the physiotherapist applies increasing pressure directly to the MTrP. In dry needling, acupuncture-like filiform needles are applied to the same point. There are two types of dry needling: superficial dry needling, which penetrates only the skin and superficial muscle, and deep dry needling, which involves inserting a needle directly into the MTrP. The sole or adjunct effectiveness of dry needling treatment targeting the trapezius and infraspinatus muscles has been investigated, particularly in patients with shoulder myofascial pain syndrome. In the study we are planning, a double-blinded efficacy trial will be conducted in patients with shoulder myofascial pain syndrome, where real and sham dry needling applications will be performed under ultrasound guidance, with both the patient and the evaluator blinded. This study design has the potential to make a significant contribution to the literature in this field."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Prospective double-blind randomized sham-controlled study.",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "In the dry needling application, patients will be blinded to the groups they are randomized into. The evaluator will also be unaware of which group the patients belong to. The practitioner will perform the procedures in both groups using ultrasound guidance, targeting the standard trigger points in the painful shoulder's trapezius and infraspinatus muscles in the study group, and targeting subcutaneous fatty tissue in the same regions in the sham group.",
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effectiveness of Dry Needling Treatment in Patients With Shoulder Myofascial Pain Syndrome",
"nctId": "NCT06338488",
"orgStudyIdInfo": {
"id": "KutahyaHSU-DRYNEEDLE-SHOULDER",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Visual Analog Scale"
},
{
"measure": "Patient-Specific Functional Scale"
},
{
"measure": "Pressure Pain Threshold Measurement"
}
],
"secondaryOutcomes": [
{
"measure": "The Shoulder Pain and Disability Index (SPADI)"
},
{
"measure": "The Quick DASH Outcome Measure"
},
{
"measure": "The 12-item Short-Form Health Survey version 2 (SF-12v2)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Kutahya Health Sciences University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-25"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-25"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-25"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Goal-Focused Emotion-Regulation Therapy (GET)"
},
{
"name": "Individual Supportive Listening (ISL)"
}
]
},
"conditionsModule": {
"conditions": [
"Cancer"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Building upon the results of a single-arm trial designed to investigate the feasibility and acceptability of a novel intervention, Goal-focused Emotion-Regulation Therapy (GET), this trial is a randomized-controlled biobehavioral pilot trial of GET versus a time-and attention matched control (Instrumental Supportive Listening; ISL) in Latino/Hispanic young adult cancer survivors. Outcomes include improved distress symptoms, emotion regulation, goal navigation skills, and changes in stress-sensitive biomarkers.Participants will be randomized to receive six sessions of GET or ISL delivered over eight weeks. In addition to indicators of intervention feasibility, the investigators will measure primary and secondary psychological outcomes prior to (T0), immediately after (T1), and twelve weeks after intervention (T2). Additionally, identified biomarkers will be measured at baseline and at T1, and T2."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "39 Years",
"minimumAge": "18 Years",
"sex": "MALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Biobehavioral Intervention for Latino/Hispanic Young Adults With Cancer",
"nctId": "NCT06338475",
"orgStudyIdInfo": {
"id": "20205703",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in Hospital Anxiety and Depression Scale (HADS)"
},
{
"measure": "Change in Systemic Pro-inflammatory Cytokine Levels (IL-6, IL-1ra, C-reactive Protein (CRP), sTNFαRII)"
},
{
"measure": "Change in Salivary Diurnal Cortisol Slope and Daily Output"
}
],
"secondaryOutcomes": [
{
"measure": "Change in Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-Sp) Subscale Score"
},
{
"measure": "Change in Career Thoughts Inventory (CTI) Global Score"
},
{
"measure": "Change in Emotion Regulation Questionnaire (ERQ) Scale Scores"
},
{
"measure": "Change in Cancer Assessment for Young Adults (CAYA-T) - Goal Navigation Score"
},
{
"measure": "Change in Emotional Approach Coping Questionnaire (EAC) Scale Scores"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of California, Irvine"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Chatbot"
},
{
"name": "Oral testing"
}
]
},
"conditionsModule": {
"conditions": [
"Tuberculosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cali",
"contacts": null,
"country": "Colombia",
"facility": "Centro Internacional de Entrenamiento e Investigaciones Medicas (CIDIEM)",
"geoPoint": {
"lat": 3.43722,
"lon": -76.5225
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The overall objective of this Aim is to design and iteratively adapt a home-based, mHealth- and oral testing facilitated strategy for implementing tuberculosis (TB) contact tracing in Cali, Colombia. Investigators will employ an iterative, community-engaged, participatory co-design process to optimize the feasibility, acceptability, usability, and appropriateness of the mobile health (mHealth) and oral testing strategy, in preparation for a future, appropriately powered implementation-effectiveness trial.This protocol includes the baseline contact tracing protocol and the procedures for determining adaptations to the mHealth strategy (i.e., nominal group technique)."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "target sample size is an anticipated 120 index persons with TB enrolled over three design cycles",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Cali Sin Tos Aim 2",
"nctId": "NCT06338462",
"orgStudyIdInfo": {
"id": "2000034128",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "R21AI174129",
"link": "https://reporter.nih.gov/quickSearch/R21AI174129",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Implementation of the mHealth strategy to assess feasibility."
},
{
"measure": "Oral specimen collection to assess feasibility."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Institute of Allergy and Infectious Diseases (NIAID)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Yale University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Aerobic training (AT)"
},
{
"name": "Resistance training (RT)"
},
{
"name": "Combined aerobic and resistance training (AT + RT)"
}
]
},
"conditionsModule": {
"conditions": [
"Non-alcoholic Fatty Liver Disease NAFLD"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Xuzhou",
"contacts": null,
"country": "China",
"facility": "Outdoor track and field facility of Xuzhou Medical University",
"geoPoint": {
"lat": 34.18045,
"lon": 117.15707
},
"state": "Jiangsu",
"status": null,
"zip": "221000"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this clinical trial is to investigate which exercise regimen is more effective in improving non-alcoholic fatty liver disease (NAFLD) in a young population. The primary questions it aims to answer are:Does aerobic training, resistance training, or a combination of both help improve liver function and glycemic and lipid parameters in NAFLD patients? Which of these three exercise regimens is more effective in improving the aforementioned parameters? Is the improvement in liver function related to bile acid metabolism?Participants will:Engage in physical exercise 4-5 times per week for two consecutive months, following a predefined exercise regimen.Have blood samples collected to test for glucose, lipids, liver function, and other parameters before starting the exercise program and after two months of completing the regimen."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "The specific exercise plan and grouping are as follows:Participants were randomly (Using an electronic random number generator) divided into four groups: control group (Control), aerobic training group (AT), resistance training group (RT), and combined aerobic and resistance training group (AT + RT), with each group consisting of 10 individuals, totaling 40 participants. All participants were young adults aged between 18 and 21 years old.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "After the data is obtained, the person analyzing the data will not know the specific grouping and participant information. The groups will be replaced by Group A, B, C, D, and the participants will be indicated by their IDs.",
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "23 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Impact of Different Exercise Modes on Bile Acid Levels and Liver Function in Patients With Non-alcoholic Fatty Liver Disease",
"nctId": "NCT06338449",
"orgStudyIdInfo": {
"id": "XZMU-2022-ZK068",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Changes in other subtypes of bile acids compared to baseline at 8 weeks"
}
],
"primaryOutcomes": [
{
"measure": "Changes in body weight compared to baseline at 8 weeks"
},
{
"measure": "Changes in Body Mass Index compared to baseline at 8 weeks"
},
{
"measure": "Changes in total cholesterol compared to baseline at 8 weeks"
},
{
"measure": "Changes in triglycerides compared to baseline at 8 weeks"
},
{
"measure": "Changes in high-density lipoprotein compared to baseline at 8 weeks"
},
{
"measure": "Changes in low-density lipoprotein compared to baseline at 8 weeks"
},
{
"measure": "Changes in alanine aminotransferase compared to baseline at 8 weeks"
},
{
"measure": "Changes in aspartate aminotransferase compared to baseline at 8 weeks"
},
{
"measure": "Changes in alkaline phosphatase compared to baseline at 8 weeks"
},
{
"measure": "Changes in gamma-glutamyl transferase compared to baseline at 8 weeks"
},
{
"measure": "Changes in direct bilirubin compared to baseline at 8 weeks"
},
{
"measure": "Changes in total bile acids compared to baseline at 8 weeks"
},
{
"measure": "Changes in adenosine deaminase compared to baseline at 8 weeks"
}
],
"secondaryOutcomes": [
{
"measure": "Changes in percentage of body fat compared to baseline at 8 weeks"
},
{
"measure": "Changes in waist-to-hip ratio compared to baseline at 8 weeks"
},
{
"measure": "Changes in blood glucose compared to baseline at 8 weeks"
},
{
"measure": "Changes in the level of insulin compared to baseline at 8 weeks"
},
{
"measure": "Changes in albumin compared to baseline at 8 weeks"
},
{
"measure": "Changes in C-reactive protein compared to baseline at 8 weeks"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Xuzhou Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-12-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-10-13"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Proton Radiation Therapy System (ProBeam)"
}
]
},
"conditionsModule": {
"conditions": [
"Tumor, Solid"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Guangzhou",
"contacts": null,
"country": "China",
"facility": "Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University",
"geoPoint": {
"lat": 23.11667,
"lon": 113.25
},
"state": "Guangdong",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This study is prospective, single-center, single-arm objective performance criteria.This trial will be conducted with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "a clinical study of prospective, single-arm objective performance criteria",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 47,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou)",
"nctId": "NCT06338436",
"orgStudyIdInfo": {
"id": "VAR-2022-05",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Effectiveness evaluation: Local tumor control rate 90 days after the proton radiation treatment completion"
},
{
"measure": "Safety evaluation: Incidence of Acute radiation injury"
},
{
"measure": "Safety evaluation: Incidence of Adverse Events based on CTCAE 5.0 criteria"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Varian, a Siemens Healthineers Company"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-11-13"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-09-26"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-12-21"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "vacuum mattress"
},
{
"name": "Standard Mattress"
}
]
},
"conditionsModule": {
"conditions": [
"Rhabdomyolysis",
"Acute Kidney Injury",
"Bariatric Surgery Candidate"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Kraków",
"contacts": null,
"country": "Poland",
"facility": "Jagiellonian University Mecical Collage",
"geoPoint": {
"lat": 50.06143,
"lon": 19.93658
},
"state": "Malopolskie",
"status": null,
"zip": "31-501"
}
]
},
"descriptionModule": {
"briefSummary": "This prospective clinical trial aimed to assess the usefulness of the usage of a vacuum mattress during laparoscopic sleeve gastrectomy (LSG) in the reduction of levels of rhabdomyolysis markers (myoglobin, creatine kinase, creatinine) and incidence of RML and AKI in the postoperative period.Method PatientsA prospective clinical trial has been conducted between January 2015 and December 2022 in a tertiary referral University Hospital (Krakow, Poland). It is designed as a single-center, prospective trial with two intervention arms. During the study, we specified 3 periods:* January 2015 - December 2016 - only standard mattresses were used* January 2017 - December 2019 - both types of mattresses were used* January 2020 - December 2022 - only vacuum mattresses were usedParticipants Patients aged ≥18 were qualified for LSG due to obesity and divided The first group (Vacuum Mattress group) are those laid on vacuum mattresses during the surgery. The control group consisted of patients for whom a standard operating mattress was used during the surgery. Patients with preoperative chronic renal failure were excluded from the study. Other exclusion criteria were perioperative complications which required postoperative hospitalization at the Intensive Care Unit and Compliance with Enhanced Recovery After Bariatric Surgery (ERABS) Protocol \\< 85%.Procedures and perioperative care All patients underwent LSG. Patients were operated in the beach chair position. In the study group, the patient was laid on vacuum mattresses during the surgery. In the case of control group patients, a standard operating mattress was used during the surgery. Perioperative care for all patients was in accordance with the ERABS protocol adopted in our center\\[\\]. Blood samples were collected on the first postoperative to measure RML markers (myoglobin, creatine kinase, creatinine). Symptoms of RML, AKI, and other complications were monitored for 30 days after surgery.End Point Criteria The primary endpoint is the incidence of postoperative AKI or biochemical or clinical diagnosis of RML which required additional treatment.Secondary endpoints is the concentrations of RML markers (myoglobin, creatine kinase, creatinine) on the first postoperative day"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1184,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Use of a Vacuum Mattress During Laparoscopic Sleeve Gastrectomy to Reduce the Concentration of Rhabdomyolysis Markers and Acute Renal Failure",
"nctId": "NCT06338423",
"orgStudyIdInfo": {
"id": "JagiellonianU-08",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidance of Rhabdomyolisis(RML) And/OR Acute Kidnay Injury (AKI)"
}
],
"secondaryOutcomes": [
{
"measure": "Concentration of myoglobin marker"
},
{
"measure": "Concentration of creatine kinase marker"
},
{
"measure": "Concentration of creatinine marker"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Jagiellonian University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2015-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Kangaroo Mother Care"
}
]
},
"conditionsModule": {
"conditions": [
"Kangaroo Mother Care",
"Oxidative Stress"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Lahore",
"contacts": null,
"country": "Pakistan",
"facility": "Services Hospital, Lahore",
"geoPoint": {
"lat": 31.558,
"lon": 74.35071
},
"state": "Punjab",
"status": null,
"zip": "54000"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to learn if Kangaroo Mother care can have effect on oxidative stress in premature neonates. It will also learn about the bonding between mother and her premature infant. The main questions it aims to answer are:* Does Kangaroo mother care lower the biomarker of oxidative stress in premature neonates?* Is Kangaroo mother care associated with mother-infant bonding? Researchers will compare Kangaroo mother care to Conventional incubator care to see if Kangaroo mother care works to have effect on oxidative stress.Participants will be:* given Kangaroo mother care on third day of life or standard incubator care for one hour* Urine sample for oxidative stress biomarker will be collected via noninvasive method before and after Kangaroo mother care or conventional incubator care from premature neonates.* Mother-infant bonding scale will be filled by mothers of enrolled premature infants before and after kangaroo mother care and conventional incubator care"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "3 Days",
"minimumAge": "3 Days",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": "KMC",
"briefTitle": "Effect of Kangaroo Mother Care on Oxidative Stress and Bonding",
"nctId": "NCT06338410",
"orgStudyIdInfo": {
"id": "UHS/Education/126-24/131",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "biomarker of Oxidative Stress (Allantoin) in urine sample of premature infants"
},
{
"measure": "Mother- Infant Bonding"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Services Hospital, Lahore"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Health Sciences Lahore"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-03-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-01"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2024-03-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-08-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "SCANN"
}
]
},
"conditionsModule": {
"conditions": [
"Alzheimer's Disease",
"Frontotemporal Degeneration (Semantic & Behavioral Variants)"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "Recent studies have shown that individual neuropsychological scores of patients with Alzheimer's disease and Associated Disorders (ADAD) are only poorly correlated to their behavioral difficulties, such as disinhibition, apathy, social decision-making or vulnerability. Recently, social \\& affective cognitive disorders have been highlighted as potential cause of social behavioral abnormalities. However, no previous studies have assessed the specific relationship between social \\& affective cognition \\& social behavior in ADAD. Our pilot study aims to explore the correlations between core and extended social \\& affective cognitive processes and social behavior as observed during the neuropsychological examination, as well as to explore the common brain regions involved in those domains."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "85 Years",
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "SOCIALIZE",
"briefTitle": "Social & Affective Cognition in Alzheimer's Disease & Associated Disorders",
"nctId": "NCT06338397",
"orgStudyIdInfo": {
"id": "2023_0455",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Correlation coefficient between the mini Social cognition & Emotional Assessment - mini-SEA - total score and the Social Behavior Observer Checklist - SBOC - score in all participants."
}
],
"secondaryOutcomes": [
{
"measure": "Correlation coefficients between the mini Social cognition & Emotional Assessment - mini-SEA - sub scores and the neuropsychological assessment (as measured by the Social Behavior Observer Checklist - SBOC - score in all participants."
},
{
"measure": "Correlation coefficient between the SBOC score with MRI markers in all participants"
},
{
"measure": "Correlation coefficient between mini-SEA sub scores & MRI markers in all participants."
},
{
"measure": "Correlation coefficients between mini-SEA sub scores with the SOCIAL50, CBI, ZBS, CSDC, SVS scales in each ADAD and controls groups."
},
{
"measure": "Correlation coefficients between SCANN sub-scores and the SBOC, SOCIAL50, CBI, ZBS, CSDC, SVS scales in each ADAD and controls groups."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "France Alzheimer"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Lille"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-05-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-05-02"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-02"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Peripheral Neuropathy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "San Francisco",
"contacts": [
{
"email": "https://www.withpower.com/[email protected]",
"name": "Michael B Gill",
"phone": "415-900-4227",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Power Life Sciences",
"geoPoint": {
"lat": 37.77493,
"lon": -122.41942
},
"state": "California",
"status": null,
"zip": "94107"
}
]
},
"descriptionModule": {
"briefSummary": "This trial aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in peripheral neuropathy clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.Ultimately, this trial endeavors to deepen our understanding of the factors impacting peripheral neuropathy clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CROSSOVER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research",
"nctId": "NCT06338384",
"orgStudyIdInfo": {
"id": "44735129",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of peripheral neuropathy patients who decide to enroll in a clinical research"
},
{
"measure": "Rate of peripheral neuropathy patients who remain in clinical trial to trial completion"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Power Life Sciences Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2025-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2024-03-22",
"filename": "ICF_000.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 67357,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-22T09:04"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Pelvic Floor exercise training"
}
]
},
"conditionsModule": {
"conditions": [
"Pelvic Floor Muscle Weakness",
"Sexuality"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "İzmir",
"contacts": null,
"country": "Turkey",
"facility": "Izmir Tinaztepe University",
"geoPoint": {
"lat": 38.41273,
"lon": 27.13838
},
"state": "Buca",
"status": null,
"zip": "35400"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this evaluate the effect of pelvic floor muscle exercises on sexual function in women of reproductive age. A randomized controlled trial was conducted in a sample of women of reproductive age, 77 women were randomly assigned to control (n=39) and training (n=38) groups. A form including questions regarding socio-demographic characteristics and the Female Sexual Function Index was applied to all women included in the study. Pelvic floor exercise training was given to the women in the training group and the Female Sexual Function Index was applied to both groups in the 1st, 2nd, and 3rd months. The differences between those who received and those who did not receive training and the effects of regular pelvic exercise on sexual function were evaluated by month.Research Hypotheses H1: Sexual function scores of women of reproductive age who regularly perform pelvic floor muscle exercises are higher than those who do not exercise.H2: Sexual function scores are higher for those who regularly exercise their pelvic floor muscles for at least two months"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 77,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "49 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of Pelvic Floor Muscle Exercise on Sexual Function",
"nctId": "NCT06338371",
"orgStudyIdInfo": {
"id": "IZTU-TEKBAŞ-001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Determining Number of Participants"
},
{
"measure": "Initial scale application"
},
{
"measure": "Distribution of participants into groups"
}
],
"secondaryOutcomes": [
{
"measure": "Providing pelvic floor exercise for training group"
},
{
"measure": "Female Sexual Function Index"
},
{
"measure": "Female Sexual Function Index"
},
{
"measure": "Female Sexual Function Index"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Serap Tekbas"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-05-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-04-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Plaque Psoriasis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "San Francisco",
"contacts": [
{
"email": "https://www.withpower.com/[email protected]",
"name": "Michael B Gill",
"phone": "415-900-4227",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Power Life Sciences",
"geoPoint": {
"lat": 37.77493,
"lon": -122.41942
},
"state": "California",
"status": null,
"zip": "94107"
}
]
},
"descriptionModule": {
"briefSummary": "The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CROSSOVER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Understanding Participation Habits Among Plaque Psoriasis Patients",
"nctId": "NCT06338358",
"orgStudyIdInfo": {
"id": "44519568",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Rate of patients who decide to enroll in a plaque psoriasis clinical research."
},
{
"measure": "Number of plaque psoriasis study participants who remain in clinical study until completion."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Power Life Sciences Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2025-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | {
"largeDocumentModule": {
"largeDocs": [
{
"date": "2024-03-22",
"filename": "ICF_000.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 67831,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-22T09:21"
}
]
}
} |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Therapeutic drug monitoring of beta-lactam"
}
]
},
"conditionsModule": {
"conditions": [
"Cardiogenic Shock",
"Post-cardiac Surgery",
"Cardiac Arrest",
"Extracorporeal Membrane Oxygenation Complication",
"Infections"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Clermont-Ferrand",
"contacts": null,
"country": "France",
"facility": "CHU de Clermont Ferrand - Hôpital Gabriel Montpied",
"geoPoint": {
"lat": 45.77966,
"lon": 3.08628
},
"state": null,
"status": null,
"zip": "63003"
},
{
"city": "Dijon",
"contacts": [
{
"email": null,
"name": "Pierre-Alain BAHR, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "CHU Dijon-Bourgogne",
"geoPoint": {
"lat": 47.31667,
"lon": 5.01667
},
"state": null,
"status": null,
"zip": "21000"
},
{
"city": "Paris",
"contacts": [
{
"email": null,
"name": "PAULINE DUREAU, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "Aphp Pitie Salpetriere",
"geoPoint": {
"lat": 48.85341,
"lon": 2.3488
},
"state": null,
"status": null,
"zip": "75013"
},
{
"city": "Rouen",
"contacts": [
{
"email": null,
"name": "Emmanuel BESNIER, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "CHU ROUEN - Hôpital Charles-Nicolle",
"geoPoint": {
"lat": 49.44313,
"lon": 1.09932
},
"state": null,
"status": null,
"zip": "76031"
},
{
"city": "Toulouse",
"contacts": [
{
"email": null,
"name": "Stéphanie RUIZ, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Camille MANE, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "Hôpital Rangueil - CHU Toulouse",
"geoPoint": {
"lat": 43.60426,
"lon": 1.44367
},
"state": null,
"status": null,
"zip": "31059"
}
]
},
"descriptionModule": {
"briefSummary": "The use of antibiotic therapy is common in intensive care units and primarily involves beta-lactams. Its optimal implementation is made difficult by the pharmacokinetic changes inherent in critically ill patients.Despite the current recommendations from the French Society of Anesthesiology and Intensive Care (SFAR) and the French Society of Pharmacology and Therapeutics (SFPT), there are no recommendations on prescription modalities for patients under veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of antibiotic therapy is common in VA-ECMO patients and their pharmacokinetic variability factors are then exacerbated.We aim to conduct a prospective, multicenter, interventional study designed to identify predictive factors for failure to achieve therapeutic target circulating concentrations of beta-lactams in patients under VA-ECMO treated with one of the studied beta-lactams"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 225,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "KAMELOT",
"briefTitle": "Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients",
"nctId": "NCT06338345",
"orgStudyIdInfo": {
"id": "38RC23.0222",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Predictive factors for failure to achieve target plasma concentrations in patients under VA-ECMO treated with Piperacillin-Tazobactam, Cefepime, or Meropenem."
},
{
"measure": "Predictive factors for failure to achieve target plasma concentrations in patients under VA-ECMO treated with Piperacillin-Tazobactam, Cefepime, or Meropenem."
},
{
"measure": "Predictive factors for failure to achieve target plasma concentrations in patients under VA-ECMO treated with Piperacillin-Tazobactam, Cefepime, or Meropenem."
},
{
"measure": "Predictive factors for failure to achieve target plasma concentrations in patients under VA-ECMO treated with Piperacillin-Tazobactam, Cefepime, or Meropenem."
},
{
"measure": "Predictive factors for failure to achieve target plasma concentrations in patients under VA-ECMO treated with Piperacillin-Tazobactam, Cefepime, or Meropenem."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Grenoble"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-09-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Colonic Neoplasms Malignant"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Breda",
"contacts": [
{
"email": "[email protected]",
"name": "Elze Lockhorst, Drs.",
"phone": "+31 613723827",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Jennifer Schreinemakers, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Netherlands",
"facility": "Amphia Hospital",
"geoPoint": {
"lat": 51.58656,
"lon": 4.77596
},
"state": "Noord-Brabant",
"status": "RECRUITING",
"zip": "4818CK"
}
]
},
"descriptionModule": {
"briefSummary": "Rationale: Approximately 13% (range 10-28%) of all colorectal cancer patients (CRC) present with an acute obstruction. Postoperative mortality after an emergency resection is known for its high risk of morbidity and mortality. Different options can be considered in the management of obstructing right sided CRC: 1) primary resection, simultaneous treatment of obstruction and tumour resection, or 2) staged treatment of the obstruction with secondary resection of the tumour. Currently, in the Netherlands, an emergency resection has been judged to be inferior to postponing surgery. Patients who present with right sided obstructive colon cancer at one of the participating hospitals are subjected to a bridge to surgery (BTS) protocol.Objective: The primary objective of this study is to determine the feasibility of BTS protocols in right sided obstructive colon cancer and reduce mortality- and morbidity (stoma rates, major- and minor complications) rates in potentially curable patients presenting with acute obstructing colon cancer.Study design: This is a multicentre, prospective registration study Study population: All patients presenting with high clinical suspicion or histologically proven right sided colon cancer and signs of obstruction of the large bowel.Intervention: Prospective registration of the implementation of bridge to surgery protocols in patients with (acute) malignant right sided obstruction of the colon, without suspicion of perforation (tumour perforation or blow out) in order to optimize patients preoperatively. The BTS approach encompasses the utilization of either ileostomy creation, stent placement or nasogastric tube for decompression, which is subsequently followed by definitive surgical treatment at a later stage. BTS also involves pre-optimization, prior to the surgical procedure, with the following approach: optimizing the nutritional health status improving the physical health status of the patient.Main study parameters/endpoints: The primary endpoint is complication-free survival (CFS) at 90 days after hospitalization. Complication is defined here as mortality and/or development of a major complication (Clavien-Dindo classification ≥3). With a total follow up of three years. Secondary endpoints: overall mortality, morbidity (stoma rates, minor complications), in hospital stay, oncologic quality of resection and other occurring adverse events."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 110,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "OCCBRIGHT",
"briefTitle": "Obstructive Colon Cancer, a Bridge to Surgery in Right Sided Obstructive Colon Cancer",
"nctId": "NCT06338332",
"orgStudyIdInfo": {
"id": "AW23.050, W19.249",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Gender"
},
{
"measure": "Age at surgery"
},
{
"measure": "ASA"
},
{
"measure": "Bodyweight"
},
{
"measure": "Height"
},
{
"measure": "Concomitant and previous therapy"
},
{
"measure": "C-reactive protein"
},
{
"measure": "Haemoglobin"
},
{
"measure": "Laboratory values"
},
{
"measure": "Leukocytes"
},
{
"measure": "Prothrombin time"
},
{
"measure": "Sodium"
},
{
"measure": "Potassium"
},
{
"measure": "Glomerular filtration rate"
},
{
"measure": "Albumin"
},
{
"measure": "Bilirubin"
},
{
"measure": "ASAT"
},
{
"measure": "ALAT"
},
{
"measure": "LDH"
},
{
"measure": "ALP"
},
{
"measure": "Gamma-GT"
},
{
"measure": "Creatinkinase"
},
{
"measure": "Phosphate"
},
{
"measure": "Lactate"
}
],
"primaryOutcomes": [
{
"measure": "Complication-free survival"
}
],
"secondaryOutcomes": [
{
"measure": "Complications overall"
},
{
"measure": "Type of surgical intervention"
},
{
"measure": "Time till surgery"
},
{
"measure": "Resection"
},
{
"measure": "TNM"
},
{
"measure": "Hospital stay"
},
{
"measure": "One year stoma rate"
},
{
"measure": "One year survival rates"
},
{
"measure": "Disease free survival rates one year"
},
{
"measure": "Disease free survival rates three years"
},
{
"measure": "Three year survival rates"
},
{
"measure": "Tumour type (obstructing, not obstructing),"
},
{
"measure": "Metastasis preoperative"
},
{
"measure": "Pre-operative diagnostics"
},
{
"measure": "Type of bridge-to-surgery"
},
{
"measure": "Nutrition (TPN/extra nutrition)"
},
{
"measure": "Consultation of other specialist"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Amphia Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Book-Sharing for Toddlers with Clefts (BOOST)"
}
]
},
"conditionsModule": {
"conditions": [
"Cleft Palate",
"Cleft Lip and Palate"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Children with clefts exhibit difficulty with language and literacy compared to children without clefts. However, little is known about interventions to address these difficulties in the cleft population. This study will test the efficacy of a parent-focused dialogic book-sharing intervention for toddlers with isolated cleft palate. The study will use a randomized controlled trial (RCT) design and Intention to Treat (ITT) analyses. Child outcomes include expressive and receptive language. Parent outcomes of interest include the frequency and quality of shared reading interactions. To assess mechanisms of action, the study will test whether changes in child outcomes are mediated by changes in parents' behavior. Analyses will also explore heterogeneity in outcomes to determine whether the intervention is more effective in certain clinical or demographic sub-groups."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 320,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "32 Months",
"minimumAge": "24 Months",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": "BOOST",
"briefTitle": "Book Sharing for Toddlers With Clefts",
"nctId": "NCT06338319",
"orgStudyIdInfo": {
"id": "23-048-E",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Frequency of Shared Reading"
},
{
"measure": "Quality of Shared Reading"
},
{
"measure": "Child Language During Reading"
}
],
"primaryOutcomes": [
{
"measure": "Expressive One Word Picture Vocabulary Test-Fourth Edition"
},
{
"measure": "Receptive One Word Picture Vocabulary Test-Fourth Edition"
},
{
"measure": "Child Language Sample"
},
{
"measure": "MacArthur-Bates Communicative Development Inventory - Computer Adaptive Test"
}
],
"secondaryOutcomes": [
{
"measure": "Child Speech Sample - Percent Consonants Correct - Revised, Total Number of Unique Consonants"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Washington"
},
{
"name": "Nationwide Children's Hospital"
},
{
"name": "Children's Hospital Los Angeles"
},
{
"name": "Ohio State University"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Seattle Children's Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Tacrolimus（FK506）"
}
]
},
"conditionsModule": {
"conditions": [
"Heart Transplant Failure"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pavia",
"contacts": [
{
"email": "[email protected]",
"name": "Ferrari Alessandra, PharmD",
"phone": "+390382503689",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Simona De Gregori",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Fondazione IRCCS Policlinico San Matteo",
"geoPoint": {
"lat": 45.19205,
"lon": 9.15917
},
"state": null,
"status": "RECRUITING",
"zip": "27100"
}
]
},
"descriptionModule": {
"briefSummary": "Heart transplant is the only effective treatment for people with advanced heart failure.Post-transplant pharmacological therapies are of fundamental importance for the survival of individuals after surgery: although considerable progress has been made for combined immunosuppressive therapies, acute cellular and especially non-cellular rejection still represents a great challenge for doctors.To verify the absence of the first signs of acute rejection, the analysis of numerous cardiac biopsies (EMB endomyocardial biopsies) is necessary during the first 12 months following the transplant.Thanks to these scheduled checks, doctors are able to identify the first symptoms of possible chronic rejection and reduce its episodes.Since the analysis of biopsies is also based on subjective interpretations, cases of erroneous conclusions are frequent.The researchers of this study aim not only to analyze the biopsies according to the current best clinical practice, but also to evaluate how much anti-rejection drug is actually contained within them.This is an analysis that is still little used for this type of transplant, which could provide very useful information to doctors.The researchers will focus their attention on one drug in particular, tacrolimus, abbreviated to \"TAC\".The amount of drug measured in biopsies will be compared with that measured in whole blood samples and in particular blood cells (peripheral blood mononuclear cells: PBMC).The genetic characteristics of each person play an important role in the success of treatment with the drug. To best interpret the results, all participants will be asked to take a blood sample to identify some characteristics of their DNA that could influence the outcome of tacrolimus therapy."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 25,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes",
"nctId": "NCT06338306",
"orgStudyIdInfo": {
"id": "08073421",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Tacrolimus quantification in an unconventional matrix"
},
{
"measure": "Tacrolimus quantification in PBMCs"
},
{
"measure": "Tacrolimus quantification in whole blood"
}
],
"secondaryOutcomes": [
{
"measure": "Genetic profile in heart transplant recipients"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Fondazione IRCCS Policlinico San Matteo di Pavia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-09"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2022-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-01-07"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Inclisiran sodium"
},
{
"name": "Rosuvastatin"
}
]
},
"conditionsModule": {
"conditions": [
"Coronary Artery Disease"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Effects of inclisiran + statins vs. statins on the morphology and vascular function of coronary vulnerable plaques, in order to provide a better treatment and more detailed imaging basis for the treatment of coronary vulnerable plaques."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "EItoCVP",
"briefTitle": "Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques",
"nctId": "NCT06338293",
"orgStudyIdInfo": {
"id": "KY20240123-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The change rate of the thinnest fibrous cap of vulnerable plaque at the target vascular lesion from baseline to one-year follow-up(△ FCT%)"
}
],
"secondaryOutcomes": [
{
"measure": "The change rate of TAV and plaque load of the target vascular lesion;"
},
{
"measure": "The change rate of lipid composition of plaque: including the lipid volume , the maximum area and angle of lipid, the length of vulnerable plaque, etc."
},
{
"measure": "The change rates of other components of plaque (fiber, calcification, crystal, macrophage)"
},
{
"measure": "The change rates of lesion OFR and target vessel OFR"
},
{
"measure": "The change rates of other indexes (low density lipoprotein level, Lp-PLA2, hs-CRP, etc.)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Nanjing First Hospital, Nanjing Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Sonara"
}
]
},
"conditionsModule": {
"conditions": [
"Opioid Use Disorder"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "Methadone is an effective treatment for severe opioid use disorder (OUD), but access is limited due to the requirement of daily observed dosing by most opioid treatment programs (OTPs). Sonara Health designed a HIPAA-compliant web-application called Sonara that features integrated video dosing recording, a tamper-evident seal, and an innovative measurement-based care (MBC) framework called the Opioid Craving Visual Analogue Scale (OC-VAS) to facilitate methadone take-homes while providing evidence of appropriate use and monitoring patient outcomes. Phase II of this SBIR aims to compare Sonara against usual take-homes to assess its impact on retention in care, opioid use, patient outcomes, and costs of care."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ROME II",
"briefTitle": "Remotely Observed Methadone Evaluation II",
"nctId": "NCT06338280",
"orgStudyIdInfo": {
"id": "VDW002",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Retention"
},
{
"measure": "Take homes received over time"
}
],
"secondaryOutcomes": [
{
"measure": "Opioid cravings"
},
{
"measure": "Urine toxicology"
},
{
"measure": "Opioid withdrawal severity"
},
{
"measure": "Health-related quality of life"
},
{
"measure": "Drug Abuse Treatment Costs Analysis"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Sonara Health"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Rett Syndrome"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Chicago",
"contacts": [
{
"email": null,
"name": "Study Coordinator",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Pallavi Patawi, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Rush University",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
},
"state": "Illinois",
"status": null,
"zip": "60612"
},
{
"city": "Boston",
"contacts": [
{
"email": null,
"name": "Study Coordinator",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "David Lieberman, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Boston Children's Hospital",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02115"
},
{
"city": "Houston",
"contacts": [
{
"email": null,
"name": "Study Coordinator",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Bernhard Suter, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Baylor College of Medicine",
"geoPoint": {
"lat": 29.76328,
"lon": -95.36327
},
"state": "Texas",
"status": null,
"zip": "77030"
}
]
},
"descriptionModule": {
"briefSummary": "The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document device use and symptom status, and will come to the clinic for 1 overnight sleep study. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year.The study will provide information on the feasibility and ease of use for families at home, biosensor data will be compared to data collected at the same time from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome, and Emerald will be developed to include movement as a measurable symptom."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "VIBRANT",
"briefTitle": "Validation of Innovative Biosensors for Rett Autonomic Symptom Tracking",
"nctId": "NCT06338267",
"orgStudyIdInfo": {
"id": "SENS-102-RSRT",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Assess breathing rate and apnea (breath holds) with RespiraSense"
},
{
"measure": "Assess heart rate variability with Vivalink VV330 ECG patch"
},
{
"measure": "Assess blood oxygen levels with Viatom Kids O2 pulse oximeter ring"
},
{
"measure": "Validate FDA-cleared Vivalink VV330 ECG patch for heart rate variability metrics in Rett syndrome compared to in-lab PSG"
},
{
"measure": "Validate ECG-derived breathing compared to in-lab PSG"
},
{
"measure": "Validate FDA-cleared RespiraSense breathing sensor in Rett syndrome compared to in-lab PSG"
},
{
"measure": "Validate FDA-cleared Viatom Kids O2 pediatric pulse oximeter ring in Rett syndrome compared to in-lab PSG and/or Nonin wristOx pulse oximeter"
},
{
"measure": "Validate Emerald ability to reliably measure breathing and sleep compared to in-lab PSG"
},
{
"measure": "Validate Emerald ability to reliably measure breathing and sleep at home compared to FDA-cleared comparator"
},
{
"measure": "Develop Emerald ability to measure daytime movement"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Rett Syndrome Research Trust"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "percussion massage therapy"
}
]
},
"conditionsModule": {
"conditions": [
"Pregnancy Complications",
"Edema Leg",
"Physiotherapy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "Istanbul Medipol University",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This study aim is to examine the effect of percussion massage therapy applied to lower extremity on pain, edema, fatigue and quality of life in pregnant women."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "The participants are blinded.",
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "40 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Efficacy of Percussion Massage Therapy Applied to the Lower Extremity on Pain, Edema in Pregnant Women",
"nctId": "NCT06338254",
"orgStudyIdInfo": {
"id": "E-10840098-772.02-5416",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The Visual Analog Scale (VAS)"
},
{
"measure": "Evaluation of edema"
},
{
"measure": "Fatigue Severity Scale (FSS)"
},
{
"measure": "Short Form-36 (SF-36)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Istanbul Medipol University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-06-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-06-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-09-04"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin"
},
{
"name": "Bovine Hydroxyapatite"
}
]
},
"conditionsModule": {
"conditions": [
"Bone Loss",
"Regenerative Inflammation"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Santiago De Compostela",
"contacts": [
{
"email": "[email protected]",
"name": "MARIO PEREZ SAYANS GARCIA, PHD, PHD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Spain",
"facility": "Faculty of Dentistry of Universidade de Santiago de Compostela",
"geoPoint": {
"lat": 42.88052,
"lon": -8.54569
},
"state": "A Coruña",
"status": "RECRUITING",
"zip": "15705"
},
{
"city": "Murcia",
"contacts": [
{
"email": "[email protected]",
"name": "FABIO CAMACHO ALONSO, PHD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Spain",
"facility": "Faculty of Dentistry University of Murcia",
"geoPoint": {
"lat": 37.98704,
"lon": -1.13004
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The clinical study aims to assess the osteogenic effects of Galibone+ in bone regeneration post-extraction of impacted mandibular third molars."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "50 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "Galibone",
"briefTitle": "Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model",
"nctId": "NCT06338241",
"orgStudyIdInfo": {
"id": "CPP2021-008391",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Bone Regeneration_Reduction in radiolucent volume"
},
{
"measure": "Bone Regeneration_bone volume"
},
{
"measure": "Bone Regeneration_bone density"
},
{
"measure": "Bone Regeneration_Fractal dimension"
}
],
"secondaryOutcomes": [
{
"measure": "Pain levels through visual analog scale"
},
{
"measure": "Clinical Inflammation evaluating by presence/absence"
},
{
"measure": "Healing measured by healing index"
},
{
"measure": "Post-surgical complications evaluated by presence or absense"
},
{
"measure": "Oral Health-related Quality of Life measured by OHIP-14 test"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Universidad de Murcia"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Mario Pérez Sayáns"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-09-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-03"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-02"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-02"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Management of Acetabular Fractures"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Grenoble",
"contacts": [
{
"email": "[email protected]",
"name": "Sarah, Pharm D",
"phone": "0033 4 76 76 75 24",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Mehdi BOUDISSA, Pr",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "Grenoble Alpes University Hospital,La tronche",
"geoPoint": {
"lat": 45.16667,
"lon": 5.71667
},
"state": null,
"status": "RECRUITING",
"zip": "38700"
}
]
},
"descriptionModule": {
"briefSummary": "Acetabular fractures are challenging fractures to treat. Many fracture patterns occur, in a deep anatomical area surrounded by numerous vascular and nervous elements, generally in a polytraumatic context . A reduction with less than 2 mm of incongruence is generally considered acceptable, limiting post-operative osteoarthritis that could rapidly require total hip arthroplasty. Due to the long learning curve, this surgery is limited to large reference centers. In the last twenty years, the main series published in the literature are small series due to the rarity of the fractures and their trauma context (loss of follow-up, polytrauma patients...). The large variety of fracture patterns according to the Letournel classification creates a spread in patient distribution and decreases the power of statistical analysis. That is the reason why big series are rare and only a few of them allow significant conclusions . The other studies are meta-analyses with their limitationsThe lack of consensus makes it difficult to interpret the results between series, so the investigators developed a decision tree to address this knowledge gap.The aim of this study is to assess and compare the results of a decisional tree for acetabular fracture in a large cohort of patients from a well-known experimental trauma center."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "OTHER"
},
"enrollmentInfo": {
"count": 250,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "FANAD",
"briefTitle": "A New Decisional Tree for the Management of Acetabular Fractures : Monocentric Observational Study",
"nctId": "NCT06338228",
"orgStudyIdInfo": {
"id": "2023-A02458-37",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The main objective of the study is to evaluate and compare the results of a decision tree for the management of acetabulum fractures (also called acetabulum) in a large cohort of patients from the trauma center at Grenoble University Hospital"
}
],
"secondaryOutcomes": [
{
"measure": "Define the prognostic factors associated with poor clinical outcomes and total hip replacement surgery"
},
{
"measure": "Compare clinical and radiological findings with the literature"
},
{
"measure": "Compare clinical and radiological findings with the literature"
},
{
"measure": "Compare clinical and radiological findings with the literature"
},
{
"measure": "Compare clinical and radiological findings with the literature"
},
{
"measure": "Compare clinical and radiological findings with the literature"
},
{
"measure": "Propose a new assessment of the traumatic hip joint based on PROMs (Patient Reported Outcomes Measures) via a dedicated digital application (Orthense by Digikare)"
},
{
"measure": "Evaluation of Outcomes and Complications of Early Weight Bearing in Older Adults"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Grenoble"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Moderate Alcohol Drinking Pattern"
},
{
"name": "Abstention"
}
]
},
"conditionsModule": {
"conditions": [
"All Cause Mortality",
"Cardiovascular Diseases",
"Invasive Cancer",
"Liver Cirrhosis",
"Type 2 Diabetes",
"Depression",
"Dementia",
"Injury Traumatic",
"Tuberculosis",
"Infections"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pamplona",
"contacts": [
{
"email": "[email protected]",
"name": "Estíbaliz Goñi, Nutritionist",
"phone": "34948425600",
"phoneExt": "80-6596",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Rafael Perez-Araluce, PharmD",
"phone": "+34948425600",
"phoneExt": "80-6672",
"role": "CONTACT"
},
{
"email": null,
"name": "Miguel A Martinez-Gonzalez, MD, MPH, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "University of Navarra",
"geoPoint": {
"lat": 42.81687,
"lon": -1.64323
},
"state": "Navarra",
"status": null,
"zip": "31008"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years).The main question it aims to answer is to test the non-inferiority advice of a moderate alcohol drinking pattern on all-cause mortality and other chronic disease like cardiovascular disease, cancer or type 2 diabetes.Participants will receive during 4 years an advice to drink alcohol following a Mediterranean Alcohol Drinking Pattern (MADP): consuming alcohol in moderation, avoidance of binge drinking and preference for red wine.Researchers will compare those who will receive a MADP advice with those who will receive an advice on abstention to see if the advice on MADP is not inferior than the abstention advice to prevent all-cause mortality and other chronic diseases."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 10000,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "UNATI",
"briefTitle": "Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality",
"nctId": "NCT06338215",
"orgStudyIdInfo": {
"id": "UNATI_2024",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "European Research Council",
"id": "101097681",
"link": null,
"type": "OTHER_GRANT"
}
]
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Comparison between groups of invasive cancer incidence with extended follow-up"
}
],
"primaryOutcomes": [
{
"measure": "Comparison between groups of the incidence of a global Index of all-cause mortality and other alcohol-related diseases"
}
],
"secondaryOutcomes": [
{
"measure": "Comparison between groups of the incidence of the most severe outcomes"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Clinica Universidad de Navarra, Universidad de Navarra"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Mavacamten"
}
]
},
"conditionsModule": {
"conditions": [
"Obstructive Hypertrophic Cardiomyopathy (oHCM)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "London",
"contacts": null,
"country": "Canada",
"facility": "London Health Science Centre (LHSC)",
"geoPoint": {
"lat": 42.98339,
"lon": -81.23304
},
"state": "Ontario",
"status": null,
"zip": "N6A 5A5"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "MAVEN",
"briefTitle": "Real-World Effectiveness of Mavacamten in Canada",
"nctId": "NCT06338202",
"orgStudyIdInfo": {
"id": "CV027-1137",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in New York Heart Association (NYHA) functional class following mavacamten treatment initiation"
}
],
"secondaryOutcomes": [
{
"measure": "Change in left ventricular outflow tract (LVOT) with Valsalva maneuver (vLVOT) gradient following mavacamten treatment initiation"
},
{
"measure": "Proportion of patients with left ventricular outflow tract (LVOT) with Valsalva maneuver gradient (vLVOT) < 20mmHg following mavacamten treatment initiation"
},
{
"measure": "Age"
},
{
"measure": "Sex at birth"
},
{
"measure": "Ethnicity"
},
{
"measure": "Employment status"
},
{
"measure": "Body mass index (BMI)"
},
{
"measure": "Obstructive hypertrophic cardiomyopathy (oHCM) disease duration"
},
{
"measure": "Proportion of patients in each New York Heart Association (NYHA) functional class II and III"
},
{
"measure": "Left ventricular outflow tract (LVOT) with Valsalva maneuver (vLVOT) gradient"
},
{
"measure": "Left ventricular ejection fraction by 2D echocardiogram (LVEFb)"
},
{
"measure": "Mavacamten dose regimen"
},
{
"measure": "Proportion of patients who discontinued mavacamten"
},
{
"measure": "Duration of treatment prior to mavacamten discontinuation"
},
{
"measure": "Left ventricular ejection fraction by 2D echocardiogram (LVEF) at the time of mavacamten treatment discontinuation"
},
{
"measure": "Proportion of patients with left ventricular ejection fraction by 2D echocardiogram (LVEF) < 50% at the time of mavacamten treatment discontinuation"
},
{
"measure": "Reason for discontinuing mavacamten treatment"
},
{
"measure": "Functional assessment schedule"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Bristol-Myers Squibb"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "The 5Ad Diet"
},
{
"name": "The Low FODMAP Diet"
}
]
},
"conditionsModule": {
"conditions": [
"Functional Bowel Disorder",
"Irritable Bowel Syndrome",
"Food Intolerance",
"Food Intolerance Syndromes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ipswich",
"contacts": [
{
"email": "[email protected]",
"name": "Camilla Bunn",
"phone": "+44 1473 338332",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Dr Fandi Ibrahim",
"phone": "+44 1473 338623",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Camilla Bunn",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Dr Fandi Ibrahim",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Dr Federica Masieri",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Martin Sinclair",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "United Kingdom",
"facility": "University of Suffolk",
"geoPoint": {
"lat": 52.05917,
"lon": 1.15545
},
"state": "Suffolk",
"status": "RECRUITING",
"zip": "IP4 1QJ"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this randomised controlled trial (RCT) is to compare the efficacy of the newly developed 5Ad diet against the widely researched low fermentable oligo-, di-, monosaccharide and polyols (FODMAP) diet in reducing gastrointestinal symptoms associated with functional bowel disorders/food intolerances.The primary aims of this RCT are to determine:* Whether the 5Ad diet is at least as effective as the low FODMAP diet in reducing gastrointestinal symptoms associated with FBDs/food intolerances.* Whether either the 5Ad diet or the low FODMAP diet are effective in reducing mental and physical fatigue.To achieve the above aims, an RCT will be conducted with the 5Ad diet in one arm vs the active phase of the low FODMAP diet in the other arm, in a cross-over design with a 7 days washout phase in between. Both dietary protocols will be followed by each participant for 7 days.Researchers will compare the results from the 2 dietary protocols in order to ascertain the superiority of one over the other in regards to 6 gastrointestinal symptoms (abdominal pain, bloating, flatulence, bowel urgency, straining and incomplete defecation), stool form and frequency of defecation."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The 5Ad Diet for Functional Bowel Disorders",
"nctId": "NCT06338189",
"orgStudyIdInfo": {
"id": "USuffolk",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Abdominal Pain"
},
{
"measure": "Abdominal Bloating"
},
{
"measure": "Flatulence"
},
{
"measure": "Bowel Urgency"
},
{
"measure": "Straining"
},
{
"measure": "Incomplete Defecation"
},
{
"measure": "Stool Form"
},
{
"measure": "Frequency of defecation"
}
],
"secondaryOutcomes": [
{
"measure": "Fatigue"
},
{
"measure": "Mental Fatigue"
},
{
"measure": "Physical Fatigue"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Suffolk"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-05-08"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "OPTIMUS-SAB clinical care pathway"
}
]
},
"conditionsModule": {
"conditions": [
"Staph Aureus Bacteremia"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates with an incidence disproportionately higher in vulnerable populations. Management according to evidence-based care parameters, in particular Infectious Diseases (ID) consultation, is associated with improved mortality. SAB management is suboptimal in Alberta compared to other jurisdictions. An Alberta-based pilot study confirmed that timely recommendations to optimize SAB care, including ID consultation, was associated with improved adherence to all evidence-based quality-of-care indicators.Leveraging this pilot work, the investigators aim to implement OPTIMUS-SAB, an enhanced model of the pilot, to optimize and standardize SAB management across Alberta. The implementation study will be a zone-based acute care site stepped wedge design. OPTIMUS-SAB will consist of a centralized SAB care team whom will receive automated notification of all blood cultures positive for S. aureus allowing them to review the patient's medical chart and make preliminary management recommendations according to an evidence-based care bundle.The investigators will evaluate adherence to evidence-based SAB quality-of-care indicators before and after OPTIMUS-SAB implementation and expect this to improve with a resultant reduction in duration of bacteremia, length of stay, readmission rates, and mortality. In turn, this will translate into cost savings for the health care system."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "HEALTH_SERVICES_RESEARCH",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1800,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Optimizing the Management of Staphylococcus Aureus Bacteremia (OPTIMUS-SAB)",
"nctId": "NCT06338176",
"orgStudyIdInfo": {
"id": "Pro00128904",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Adherence to quality-of-care indicators"
}
],
"secondaryOutcomes": [
{
"measure": "Length of stay"
},
{
"measure": "Hospital re-admission rates"
},
{
"measure": "All-cause mortality"
},
{
"measure": "In hospital mortality"
},
{
"measure": "Costing evaluation"
},
{
"measure": "Implementation evaluation"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Alberta Health services"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Alberta"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-10-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Polihexanide-based bundle"
},
{
"name": "Standard bundle"
}
]
},
"conditionsModule": {
"conditions": [
"Surgical Site Infection",
"Surgical Procedures, Operative"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Firenze",
"contacts": [
{
"email": "[email protected]",
"name": "Marco Scatizzi, MD",
"phone": "393474137246",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "OSpedale Santa Maria Annunziata",
"geoPoint": {
"lat": 43.77925,
"lon": 11.24626
},
"state": "FI",
"status": null,
"zip": "50012"
},
{
"city": "Macerata",
"contacts": [
{
"email": "[email protected]",
"name": "Massimo Sartelli, MD",
"phone": "+393405369701",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "Ospedale Civile di Macerata",
"geoPoint": {
"lat": 43.29789,
"lon": 13.45293
},
"state": "MC",
"status": null,
"zip": "62100"
},
{
"city": "Roma",
"contacts": [
{
"email": "[email protected]",
"name": "Marco Catarci, MD",
"phone": "+393298610040",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Michele Benedetti, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Paolo Ciano, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Ospedale Sandro Pertini",
"geoPoint": {
"lat": 41.89193,
"lon": 12.51133
},
"state": "RM",
"status": null,
"zip": "00157"
}
]
},
"descriptionModule": {
"briefSummary": "This is a randomized controlled, prospective, multicenter superiority trial with two parallel treatment groups and single blinding (local investigators performing postoperative follow up will be blinded for group allocation), with prospective enrollment planned from July 2024 to June 2025 in 20 Italian surgical centers. All patients undergoing elective major gastro-intestinal (GI) tract surgery (upper GI, HPB, \\& lower GI) will be included in a prospective database after written informed consent. A total of 2,000 patients is expected based on a mean of 100 cases per center."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Randomized controlled prospective multicenter",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "Assessor of the primary outcome will be masked concerning arm allocation",
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 2000,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "POSSIBLE",
"briefTitle": "Polihexanide SSIs Measures Bundle (PSMB) During Enhanced Recovery After Major Digestive Surgery",
"nctId": "NCT06338163",
"orgStudyIdInfo": {
"id": "POSSIBLE 1.6",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Patient-reported outcome measures"
}
],
"primaryOutcomes": [
{
"measure": "Surgical Site Infections rate"
},
{
"measure": "Incisional (superficial and deep) Surgical Site Infections rate"
},
{
"measure": "Infectious morbidity rates"
}
],
"secondaryOutcomes": [
{
"measure": "Anastomotic leakage rates"
},
{
"measure": "Overall morbidity rates"
},
{
"measure": "Major morbidity rates"
},
{
"measure": "Comprehensive complication index"
},
{
"measure": "Overall length of postoperative hospital stay"
},
{
"measure": "Readmission rates"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Associazione Chirurghi Ospedalieri Italiani"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Marco Catarci"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-09-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Multiple Myeloma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "New York",
"contacts": [
{
"email": "[email protected]",
"name": "Cesar Rodriguez Valdes, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Katherine Vandris",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Cesar Rodriguez Valdes",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Mount Sinai Health System",
"geoPoint": {
"lat": 40.71427,
"lon": -74.00597
},
"state": "New York",
"status": null,
"zip": "10029"
}
]
},
"descriptionModule": {
"briefSummary": "This will be a 2 year study to evaluate and improve cancer sequencing as applied to the characterization of tumor molecular make-up and the identification of novel therapeutics (n=100). Participants who will undergo tumor biopsy for management of multiple myeloma (MM) will self-refer to the study or be referred by their treating physician. Participants will initially meet with a clinician to review study consents and provide medical, medication, and family history information. After informed consent, biospecimen samples from peripheral blood, cheek swab, and tumor samples from bone marrow (aspirate and biopsy), peripheral blood, or any mass/fluid containing tumor cells will be obtained (from procedures indicated as part of their standard oncology care) for cancer sequencing (CS) (whole exome sequencing of germline and tumor genomes, RNA sequencing of tumor transcriptome, single cell, and CyTOF analysis). CS data will be interpreted via somatic variation identification, network modeling, and cancer transcriptome profiling to facilitate mapping activity levels of genes to networks and for identifying genes activated or dysregulated in cancer cells. Sequencing and analysis will be performed at the Genomics Core Facility at the Icahn School of Medicine at Mount Sinai. In instances where internal sequencing capabilities do not allow for certain types of analysis, de-identified samples or data may be sent out to third parties for additional analysis. The study will be using GenPath, a division of BioReference® Health, LLC for this project which is a CLIA certified lab. All genetic tests will be performed in a CLIA certified lab and all tests will be FDA or NYS approved. The RNA Sequencing test will receive NYS Department of Health (Wadsworth Center) approval before results are provided to physicians and patients. Samples will be de-identified and processed by the Mount Sinai Human Immune Monitoring Core (HIMC) before being sent to an external CLIA-certified lab for sequencing and analysis. Interpretation will be performed by a multidisciplinary team that includes genomicists, pathologists, and clinicians familiar with the particular cancer diagnosed in the participant. Once results are available, they will be shared with the participant and treating physician during a follow-up results session and any findings obtained explained. This study is not intended to implement findings, only to report them."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Precision Medicine Study",
"nctId": "NCT06338150",
"orgStudyIdInfo": {
"id": "STUDY-23-00503",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Icahn School of Medicine at Mount Sinai",
"id": "GCO 19-0175",
"link": null,
"type": "OTHER_GRANT"
},
{
"domain": null,
"id": "5R01CA244899",
"link": "https://reporter.nih.gov/quickSearch/5R01CA244899",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Total number of somatic Single-nucleotide variants (SNVs) per patient"
}
],
"secondaryOutcomes": [
{
"measure": "Total number of somatic insertions (INS) per patient"
},
{
"measure": "Total number of somatic deletions (DEL) per patient"
},
{
"measure": "Number of SNVs per megabase of the MM genome"
},
{
"measure": "Number of INS per megabase of the MM genome"
},
{
"measure": "Number of DEL per megabase of the MM genome"
},
{
"measure": "Number of mutations per megabase among MM subgroups"
},
{
"measure": "Number of mutations per megabase among genomic regions for all MM and mutational subgroups"
},
{
"measure": "Gene mutations identified"
},
{
"measure": "Chromosomal abnormalities identified"
},
{
"measure": "Molecular signatures identified"
},
{
"measure": "Established Prognostic markers identified"
},
{
"measure": "Somatic variants identified as targets of FDA-approved drugs (pharmacogenomics variant data)"
},
{
"measure": "Network-informed key driver variants identified"
},
{
"measure": "Transcriptome variations identified"
},
{
"measure": "Germline mutations identified in cancer predisposition genes"
},
{
"measure": "FDA approved drugs available that block enzymes produced in those pathways identified"
},
{
"measure": "Treatment recommended by computational pipeline based on patient's clinical and genetic"
},
{
"measure": "Germline whole exome sequencing profile"
},
{
"measure": "Tumor genome whole exome sequencing profile"
},
{
"measure": "Tumor transcriptome profile"
},
{
"measure": "Single-cell sequencing profile"
},
{
"measure": "Cytometric profile"
},
{
"measure": "Signaling Pathways associated"
},
{
"measure": "Enzymes associated with each signaling pathway identified"
},
{
"measure": "Improvement of cancer sequencing-guided treatment recommendations by machine learning"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Cancer Institute (NCI)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Icahn School of Medicine at Mount Sinai"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Holmium Yag laser"
}
]
},
"conditionsModule": {
"conditions": [
"Renal Stone"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shibīn Al Kawm",
"contacts": null,
"country": "Egypt",
"facility": "Hossam Kandeel",
"geoPoint": {
"lat": 30.55258,
"lon": 31.00904
},
"state": "State Or Province",
"status": null,
"zip": "32511"
}
]
},
"descriptionModule": {
"briefSummary": "Rcompare high-energy versus low-energy laser settings in renal stone lithotripsy using low power machines) Holmium YAG 30 watts, examining their respective advantages, limitations, and overall efficacy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 160,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Comparison of High and Low Pulse Energy Dusting Protocols Using Holmium: YAG-laser in Flexible Ureteroscopy for Renal Stones Treatment",
"nctId": "NCT06338137",
"orgStudyIdInfo": {
"id": "4-2024urol",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Stone free rates"
}
],
"secondaryOutcomes": [
{
"measure": "Preoperative complications"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Menoufia University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-01-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-04"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-08-25"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-08-25"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Triglyceride glucose index"
}
]
},
"conditionsModule": {
"conditions": [
"Sepsis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Assiut",
"contacts": [
{
"email": "[email protected]",
"name": "Dina Hamad, Assist.Prof",
"phone": "+201063040703",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Egypt",
"facility": "Assuit University Hospital",
"geoPoint": {
"lat": 27.18096,
"lon": 31.18368
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Sepsis is defined as a dysregulated host response to infection . Despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years,There are several biomarkers that have already been studied for the early diagnosis of sepsis. Some of these markers can be used in risk prediction and monitoring the outcome of sepsis .Some of these markers as procalcitonin and CD14, are costly and not feasible options for low- and middle-income countries . While other biomarkers are feasible and accessible to be evaluated as Triglyceride\\\\glucose index (TyG) , Relative Distributive Width of red blood corpuscles to albumin ratio (RAR), C-reactive protein,Neutrophile \\\\Lympocyte ratio and serum lactate levels ."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Value of Laboratory Biomarkers in Prediction of Outcome in Septic Patients",
"nctId": "NCT06338124",
"orgStudyIdInfo": {
"id": "David Ibrahim",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mortality"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Egymedicalpedia"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-03-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-03-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "ELISA Sepsis Biomarkers dosage"
}
]
},
"conditionsModule": {
"conditions": [
"Sepsis Syndrome",
"Emergency Department",
"Biomarker"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cluj-Napoca",
"contacts": null,
"country": "Romania",
"facility": "Cluj County Hospital Emergency Department",
"geoPoint": {
"lat": 46.76667,
"lon": 23.6
},
"state": "Cluj",
"status": null,
"zip": "400006"
}
]
},
"descriptionModule": {
"briefSummary": "This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 67,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "90 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Interventions Meant to Improve the Outcome of Critical Care Patients in the ED",
"nctId": "NCT06338111",
"orgStudyIdInfo": {
"id": "2461",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Can we better predict mortality in septic patients from the Emergency Department?"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Iuliu Hatieganu University of Medicine and Pharmacy"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-16"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-12-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-11-09"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "8-week wellness and relaxation meditation program"
}
]
},
"conditionsModule": {
"conditions": [
"Stress",
"Burnout, Professional"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Boston",
"contacts": null,
"country": "United States",
"facility": "Angell Animal Medical Center,",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02130"
}
]
},
"descriptionModule": {
"briefSummary": "This quantitative study assesses the effects of meditation and relaxation practices on the reduction of burnout and stress in veterinary care workers. Assessments at baseline will include the Perceived Stress Scale (PSS) and Maslach Burnout Toolkit, and the same questionnaires were collected in Week 8 and Week 16. The Google form questionnaire will ask the participant for their email address. The form will also include a question eliciting interest in participation in the 8-weeks Heartfulness Meditation program. The program will include tools that promote a heart-based nurturing environment focusing on relaxation, and tools to cope with burnout."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 74,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of an 8-week Heartfulness Meditation Program on Burnout and Stress at Veterinary Specialty Hospital",
"nctId": "NCT06338098",
"orgStudyIdInfo": {
"id": "HFNVSH.001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Assess the current level of Anxiety"
},
{
"measure": "Changes level of Stress"
},
{
"measure": "Assess the current level of Burnout"
},
{
"measure": "Changes level of Burnout"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Angell Animal Medical Center"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Heartfulness Institute"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-10-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-02"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-10-02"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-02-28"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "emotional liberation technique"
}
]
},
"conditionsModule": {
"conditions": [
"Menopause"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": [
{
"email": "[email protected]",
"name": "MERYEM VURAL ŞAHİN",
"phone": "05535344779",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Meltem UĞURLU",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Derya Yüksel KOÇAK",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Turkey",
"facility": "family health center no. 1 in Çayyolu",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": "Çankaya",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study is to determine the effect of EFT (Emotional Freedom Technique), a nonpharmacological method, on menopausal symptoms and depression in postmenopausal women. By determining the effectiveness of the Emotional Freedom Technique, the applicability of non-pharmacological method treatment in women with depression and menopausal symptoms in postmenopausal period will be proven. As a result of the study, if a positive effect on menopausal symptoms and depression is found in women with EFT, it can be recommended as an evidence-based alternative method in midwifery and nursing care."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "the groups with a conventional therapy control group",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": null,
"sex": "FEMALE",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Emotional Freedom Technique (EFT) on Depression in Postmenopausal Women",
"nctId": "NCT06338085",
"orgStudyIdInfo": {
"id": "meryemvrlshn00000000002",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Beck Depression Scale"
}
],
"secondaryOutcomes": [
{
"measure": "Menopause Rating Scale (MRS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Meryem Vural Şahin"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-05-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-05"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-11"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Type 1 Diabetes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Madrid",
"contacts": null,
"country": "Spain",
"facility": "Lía Nattero-Chávez",
"geoPoint": {
"lat": 40.4165,
"lon": -3.70256
},
"state": null,
"status": null,
"zip": "28034"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this observational study is to assess the effectiveness of automatic insulin infusion in responding to changes in insulin sensitivity throughout various phases of the menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an advanced closed-loop system. By gaining insights into both the limitations and effectiveness of this adaptation, we aim to inform the enhancement of control algorithms and learning strategies within closed-loop systems. This research is especially vital for addressing the distinct challenges that women commonly encounter in maintaining glycemic control."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 119,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "50 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "DIABETEXX/1",
"briefTitle": "Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1).",
"nctId": "NCT06338072",
"orgStudyIdInfo": {
"id": "DIABETEXX/1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Time in range"
}
],
"secondaryOutcomes": [
{
"measure": "Time below range"
},
{
"measure": "Time above range"
},
{
"measure": "Caloric intake"
},
{
"measure": "Temperature"
},
{
"measure": "Photoplethysmography"
},
{
"measure": "Accelerometry"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Universitat Politècnica de València"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-03"
},
"studyFirstPostDateStruct": {
"date": "2024-03-29"
}
}
} | false | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.